KR20130130995A - A preparation method of an effervescent tablet comprising an extract of kyungokgo or crude drug - Google Patents
A preparation method of an effervescent tablet comprising an extract of kyungokgo or crude drug Download PDFInfo
- Publication number
- KR20130130995A KR20130130995A KR1020120054704A KR20120054704A KR20130130995A KR 20130130995 A KR20130130995 A KR 20130130995A KR 1020120054704 A KR1020120054704 A KR 1020120054704A KR 20120054704 A KR20120054704 A KR 20120054704A KR 20130130995 A KR20130130995 A KR 20130130995A
- Authority
- KR
- South Korea
- Prior art keywords
- mixture
- flavor
- weight
- acid
- extract
- Prior art date
Links
- 239000007938 effervescent tablet Substances 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims description 17
- 239000000284 extract Substances 0.000 title abstract description 55
- 239000003814 drug Substances 0.000 title description 7
- 229940079593 drug Drugs 0.000 title description 5
- 238000004519 manufacturing process Methods 0.000 claims abstract description 47
- 235000020710 ginseng extract Nutrition 0.000 claims abstract description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 8
- 244000273928 Zingiber officinale Species 0.000 claims abstract description 3
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 3
- 235000008397 ginger Nutrition 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 99
- 239000000796 flavoring agent Substances 0.000 claims description 50
- 235000019634 flavors Nutrition 0.000 claims description 49
- 229910052640 jadeite Inorganic materials 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 34
- 241000283707 Capra Species 0.000 claims description 30
- 239000003381 stabilizer Substances 0.000 claims description 27
- 238000002156 mixing Methods 0.000 claims description 25
- 235000002639 sodium chloride Nutrition 0.000 claims description 21
- 230000003078 antioxidant effect Effects 0.000 claims description 20
- 235000003599 food sweetener Nutrition 0.000 claims description 20
- 150000005846 sugar alcohols Chemical class 0.000 claims description 20
- 229930003231 vitamin Natural products 0.000 claims description 18
- 235000013343 vitamin Nutrition 0.000 claims description 18
- 239000011782 vitamin Substances 0.000 claims description 18
- 229940088594 vitamin Drugs 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 17
- 239000003765 sweetening agent Substances 0.000 claims description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 16
- 239000004604 Blowing Agent Substances 0.000 claims description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 16
- 230000036541 health Effects 0.000 claims description 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 14
- 240000004371 Panax ginseng Species 0.000 claims description 13
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 13
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 13
- 235000013373 food additive Nutrition 0.000 claims description 13
- 239000002778 food additive Substances 0.000 claims description 13
- 235000008434 ginseng Nutrition 0.000 claims description 13
- 239000012676 herbal extract Substances 0.000 claims description 13
- 150000007524 organic acids Chemical class 0.000 claims description 13
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 12
- 239000011230 binding agent Substances 0.000 claims description 12
- 239000000314 lubricant Substances 0.000 claims description 12
- 235000001014 amino acid Nutrition 0.000 claims description 11
- 229940024606 amino acid Drugs 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 11
- 239000007884 disintegrant Substances 0.000 claims description 10
- 239000008101 lactose Substances 0.000 claims description 10
- 239000003755 preservative agent Substances 0.000 claims description 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 8
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 8
- 229930195725 Mannitol Natural products 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 229930003268 Vitamin C Natural products 0.000 claims description 8
- 239000011575 calcium Substances 0.000 claims description 8
- 239000000594 mannitol Substances 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 8
- 235000019154 vitamin C Nutrition 0.000 claims description 8
- 239000011718 vitamin C Substances 0.000 claims description 8
- 239000003086 colorant Substances 0.000 claims description 7
- -1 hydride Chemical compound 0.000 claims description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims description 7
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 7
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- 230000001093 anti-cancer Effects 0.000 claims description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
- 239000003205 fragrance Substances 0.000 claims description 6
- 229960001031 glucose Drugs 0.000 claims description 6
- 241000411851 herbal medicine Species 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000001103 potassium chloride Substances 0.000 claims description 6
- 235000011164 potassium chloride Nutrition 0.000 claims description 6
- 230000002335 preservative effect Effects 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 5
- 229920001353 Dextrin Polymers 0.000 claims description 5
- 240000002045 Guettarda speciosa Species 0.000 claims description 5
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 5
- 240000006079 Schisandra chinensis Species 0.000 claims description 5
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 5
- 240000008866 Ziziphus nummularia Species 0.000 claims description 5
- 235000019425 dextrin Nutrition 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 235000012907 honey Nutrition 0.000 claims description 5
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 5
- 235000005985 organic acids Nutrition 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 5
- 239000010865 sewage Substances 0.000 claims description 5
- 235000000346 sugar Nutrition 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 4
- 239000004321 EU approved sweetener Substances 0.000 claims description 4
- 239000004386 Erythritol Substances 0.000 claims description 4
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 claims description 4
- 235000019414 erythritol Nutrition 0.000 claims description 4
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 4
- 229940009714 erythritol Drugs 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 235000010356 sorbitol Nutrition 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 239000000454 talc Substances 0.000 claims description 4
- 229910052623 talc Inorganic materials 0.000 claims description 4
- 235000012222 talc Nutrition 0.000 claims description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 claims description 3
- 108010011485 Aspartame Proteins 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 3
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 3
- 239000006035 Tryptophane Substances 0.000 claims description 3
- 239000000605 aspartame Substances 0.000 claims description 3
- 235000010357 aspartame Nutrition 0.000 claims description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 3
- 229960003438 aspartame Drugs 0.000 claims description 3
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
- 229960003415 propylparaben Drugs 0.000 claims description 3
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 claims description 3
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 3
- 229940081974 saccharin Drugs 0.000 claims description 3
- 235000019204 saccharin Nutrition 0.000 claims description 3
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims description 3
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 claims description 3
- 239000000176 sodium gluconate Substances 0.000 claims description 3
- 235000012207 sodium gluconate Nutrition 0.000 claims description 3
- 229940005574 sodium gluconate Drugs 0.000 claims description 3
- 239000001433 sodium tartrate Substances 0.000 claims description 3
- 229960002167 sodium tartrate Drugs 0.000 claims description 3
- 235000011004 sodium tartrates Nutrition 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 229960004799 tryptophan Drugs 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- 244000215068 Acacia senegal Species 0.000 claims description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 2
- 244000144730 Amygdalus persica Species 0.000 claims description 2
- 244000099147 Ananas comosus Species 0.000 claims description 2
- 235000007119 Ananas comosus Nutrition 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- 235000004936 Bromus mango Nutrition 0.000 claims description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 claims description 2
- 235000005979 Citrus limon Nutrition 0.000 claims description 2
- 240000004307 Citrus medica Species 0.000 claims description 2
- 244000131522 Citrus pyriformis Species 0.000 claims description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- 244000241257 Cucumis melo Species 0.000 claims description 2
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 claims description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 2
- 240000009088 Fragaria x ananassa Species 0.000 claims description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 229920000084 Gum arabic Polymers 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- 240000007228 Mangifera indica Species 0.000 claims description 2
- 235000014826 Mangifera indica Nutrition 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 240000000249 Morus alba Species 0.000 claims description 2
- 235000008708 Morus alba Nutrition 0.000 claims description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- 244000018633 Prunus armeniaca Species 0.000 claims description 2
- 235000009827 Prunus armeniaca Nutrition 0.000 claims description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- 229910004298 SiO 2 Inorganic materials 0.000 claims description 2
- 239000001744 Sodium fumarate Substances 0.000 claims description 2
- 235000009184 Spondias indica Nutrition 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- 235000011941 Tilia x europaea Nutrition 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 229930003451 Vitamin B1 Natural products 0.000 claims description 2
- 229930003779 Vitamin B12 Natural products 0.000 claims description 2
- 229930003471 Vitamin B2 Natural products 0.000 claims description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 2
- 240000006365 Vitis vinifera Species 0.000 claims description 2
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 2
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000000205 acacia gum Substances 0.000 claims description 2
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 2
- 229960004998 acesulfame potassium Drugs 0.000 claims description 2
- 239000000619 acesulfame-K Substances 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 229960004365 benzoic acid Drugs 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 239000007958 cherry flavor Substances 0.000 claims description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 2
- 229960000913 crospovidone Drugs 0.000 claims description 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 229960002737 fructose Drugs 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 235000001727 glucose Nutrition 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- 239000000832 lactitol Substances 0.000 claims description 2
- 235000010448 lactitol Nutrition 0.000 claims description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 2
- 229960003451 lactitol Drugs 0.000 claims description 2
- 239000004571 lime Substances 0.000 claims description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 2
- 239000001095 magnesium carbonate Substances 0.000 claims description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 2
- 239000000347 magnesium hydroxide Substances 0.000 claims description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 2
- 239000000395 magnesium oxide Substances 0.000 claims description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 229960002216 methylparaben Drugs 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 239000007968 orange flavor Substances 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 235000019161 pantothenic acid Nutrition 0.000 claims description 2
- 239000011713 pantothenic acid Substances 0.000 claims description 2
- 229940055726 pantothenic acid Drugs 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 2
- 229960002477 riboflavin Drugs 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 235000019294 sodium fumarate Nutrition 0.000 claims description 2
- 229940005573 sodium fumarate Drugs 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 2
- 229940013618 stevioside Drugs 0.000 claims description 2
- 235000019202 steviosides Nutrition 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 229960003080 taurine Drugs 0.000 claims description 2
- 229960003495 thiamine Drugs 0.000 claims description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 2
- 239000004408 titanium dioxide Substances 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 235000010374 vitamin B1 Nutrition 0.000 claims description 2
- 239000011691 vitamin B1 Substances 0.000 claims description 2
- 235000019163 vitamin B12 Nutrition 0.000 claims description 2
- 239000011715 vitamin B12 Substances 0.000 claims description 2
- 235000019164 vitamin B2 Nutrition 0.000 claims description 2
- 239000011716 vitamin B2 Substances 0.000 claims description 2
- 235000019158 vitamin B6 Nutrition 0.000 claims description 2
- 239000011726 vitamin B6 Substances 0.000 claims description 2
- 229940011671 vitamin b6 Drugs 0.000 claims description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 2
- VRVKOZSIJXBAJG-TYYBGVCCSA-M monosodium fumarate Chemical compound [Na+].OC(=O)\C=C\C([O-])=O VRVKOZSIJXBAJG-TYYBGVCCSA-M 0.000 claims 2
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- 241000361919 Metaphire sieboldi Species 0.000 claims 1
- 229910000394 calcium triphosphate Inorganic materials 0.000 claims 1
- 235000011087 fumaric acid Nutrition 0.000 claims 1
- 235000005152 nicotinamide Nutrition 0.000 claims 1
- 239000011570 nicotinamide Substances 0.000 claims 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims 1
- RFWLACFDYFIVMC-UHFFFAOYSA-D pentacalcium;[oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O RFWLACFDYFIVMC-UHFFFAOYSA-D 0.000 claims 1
- VILMUCRZVVVJCA-UHFFFAOYSA-M sodium glycolate Chemical compound [Na+].OCC([O-])=O VILMUCRZVVVJCA-UHFFFAOYSA-M 0.000 claims 1
- 229940071117 starch glycolate Drugs 0.000 claims 1
- 238000011084 recovery Methods 0.000 abstract description 5
- 235000015468 Lycium chinense Nutrition 0.000 abstract description 3
- 244000126002 Ziziphus vulgaris Species 0.000 abstract description 3
- 235000008216 herbs Nutrition 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract 2
- 240000001810 Angelica gigas Species 0.000 abstract 1
- 235000018865 Angelica gigas Nutrition 0.000 abstract 1
- 241000212948 Cnidium Species 0.000 abstract 1
- 241000207901 Cuscuta Species 0.000 abstract 1
- 241000305492 Gastrodia Species 0.000 abstract 1
- 244000241872 Lycium chinense Species 0.000 abstract 1
- 241001618264 Rubus coreanus Species 0.000 abstract 1
- 241000124703 Torilis Species 0.000 abstract 1
- 230000003578 releasing effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 25
- 235000013305 food Nutrition 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 239000003826 tablet Substances 0.000 description 20
- 239000000843 powder Substances 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 9
- 239000003963 antioxidant agent Substances 0.000 description 9
- 235000013361 beverage Nutrition 0.000 description 9
- 238000005187 foaming Methods 0.000 description 9
- 229960001375 lactose Drugs 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 235000006708 antioxidants Nutrition 0.000 description 8
- 230000003833 cell viability Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 108010093894 Xanthine oxidase Proteins 0.000 description 7
- 102100033220 Xanthine oxidase Human genes 0.000 description 7
- 239000001506 calcium phosphate Substances 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 7
- 229960001855 mannitol Drugs 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 229960002920 sorbitol Drugs 0.000 description 7
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 7
- 238000000605 extraction Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 5
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 5
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000004088 foaming agent Substances 0.000 description 5
- 235000013376 functional food Nutrition 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 229940032147 starch Drugs 0.000 description 5
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 5
- 229940078499 tricalcium phosphate Drugs 0.000 description 5
- 235000019731 tricalcium phosphate Nutrition 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000000638 solvent extraction Methods 0.000 description 4
- 239000007916 tablet composition Substances 0.000 description 4
- 238000003809 water extraction Methods 0.000 description 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 244000241838 Lycium barbarum Species 0.000 description 3
- 235000015459 Lycium barbarum Nutrition 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229940077731 carbohydrate nutrients Drugs 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229960004106 citric acid Drugs 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000002075 main ingredient Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960004543 anhydrous citric acid Drugs 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000019691 monocalcium phosphate Nutrition 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 239000010802 sludge Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000000972 4,5-dimethylthiazol-2-yl group Chemical group [H]C([H])([H])C1=C(N=C(*)S1)C([H])([H])[H] 0.000 description 1
- HOMSOWZTBJWNHP-UHFFFAOYSA-N 5-chlorothiadiazole Chemical compound ClC1=CN=NS1 HOMSOWZTBJWNHP-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 239000009122 Saeng-Ji-Hwang Substances 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- MSJMDZAOKORVFC-SEPHDYHBSA-L disodium fumarate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C\C([O-])=O MSJMDZAOKORVFC-SEPHDYHBSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229940029988 ginseng preparation Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010409 ironing Methods 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- VDYCLYGKCGVBHN-UHFFFAOYSA-N pachymaic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC(=C)C(C)C)C(O)=O)C(O)CC21C VDYCLYGKCGVBHN-UHFFFAOYSA-N 0.000 description 1
- SRDNLMOBFKJOSD-UHFFFAOYSA-N pachymic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C(O)=O)C(O)CC21C SRDNLMOBFKJOSD-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
- A23L2/395—Dry compositions in a particular shape or form
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/40—Effervescence-generating compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/56—Flavouring or bittering agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 경옥고, 또는 홍삼, 오가피, 오미자, 당귀, 구기자, 사상자, 복분자, 토사자, 천궁, 천마, 건강, 대추 등의 한약재 추출물을 함유한 발포정의 제조방법에 관한 것이다.The present invention relates to a method of producing effervescent tablets containing medicinal herbs such as jadeite, or red ginseng, ogapi, Schisandra chinensis, Angelica, goji berry, casualty, Bokbunja, Tosa, Cheongung, Cheonma, Health, Jujube.
[문헌 1] Ishiyama M. etal, 1996. Bio Pharm Bull 19: 1518-1520Ishiyama M. etal, 1996. Bio Pharm Bull 19: 1518-1520
[문헌 2] Blois MS. 1958. Nature 181:1199-1203
2 Blois MS. 1958.Nature 181: 1199-1203
본 발명은 경옥고 또는 산양삼 추출물을 함유한 발포정의 제조방법에 관한 것이다. The present invention relates to a method for producing effervescent tablets containing jade or goat ginseng extract.
경옥고는 동의보감에 기록되어 있는 건강증진 관련 전통소재로서 인삼, 백봉령, 생지황, 꿀 등과, 하수오, 맥문동, 헛개를 추가하여 사용하는 우리나라 전통의 처방전이며, 경옥고 및 천연물을 추출, 가용성 성분의 수득율을 높여서 식품에 첨가하면 경옥고 및 천연물내의 사포닌과 파치만(베타글루칸), 파치믹산 등의 효과로 피로회복, 면역기능 강화, 피부보호와 보습, 항노화 등의 효과가 배가될 수 있으며, 경옥고 처방 소재를 비타민 및 무기질과 혼합하여 발포형태의 제형을 개발하여 인체에 효능이 뛰어나고, 휴대 및 복용이 간편하고, 남녀노소 누구나 손쉽게 영양 보충 및 건강 증진에 도움이 되는 제품을 제공할 수 있다.Gyeongokgo is a traditional medicine related to health promotion recorded in Dongbobogam. It is a prescription made in Korea by adding ginseng, Baekbongryeong, Saenghwanghwang, honey, sewage, macmundong, and huts, extracting jadeite and natural products and increasing the yield of soluble ingredients. When added to food, the effects of saponin, pacman (betaglucan), and pachymic acid in jadeite and natural products can double the effects of fatigue, strengthening immune function, protecting skin, moisturizing and anti-aging. By mixing with vitamins and minerals to develop a foamed formulation, it is excellent for the human body, easy to carry and take, and can provide products that help nutrition and health for all ages.
일반적으로 발포정은 정제(tablet) 형태의 제형으로 이 발포정을 물에 첨가되면 물 속에서 기포를 내면서 용해되어 종래 정제가 가지고 있는 성분이 수용액에 존재하게 되고 이러한 성분들이 체내에 속효성, 지효성으로 이 수용액을 섭취함으로써 효능을 증가시키는데 있다.In general, effervescent tablets are tablet-type formulations. When the effervescent tablets are added to water, the effervescent tablets are bubbled in water to dissolve and the components of the conventional tablets are present in the aqueous solution. It is to increase the efficacy by ingesting an aqueous solution.
상기에서 언급한 것처럼 발포정은 식품, 의약, 보건 및 환경 분야에서 널리 사용되고 있으나 상대적으로 식품분야에서는 아직도 많은 사용이 이루어지지 않고 있다. 발포정은 물에 용해되어 최종적인 제형이 수용액 형태인데, 식품 관련 분야에서 수용액 제형은 보통 음료가 많이 사용되고 있으나, 이러한 음료는 아직도 캔, PET, 유리병과 같은 용기에 충진되어 상품으로 제공되기 때문이다.As mentioned above, effervescent tablets are widely used in the food, medicine, health and environment fields, but relatively little are still used in the food field. Effervescent tablets are dissolved in water and the final formulation is in the form of an aqueous solution. Aqueous formulations are commonly used in food-related fields, but these beverages are still filled in containers such as cans, PET, and glass bottles to be provided as commodities.
그러나, 상기 문헌의 어디에도 경옥고 또는 산양삼 추출물을 함유한 발포정의 제조방법에 대하여 개시되거나 교시된 바가 없다. However, none of this document discloses or teaches a method for producing effervescent tablets containing jadeite or goat's ginseng extract.
따라서 본 연구는 기존의 경옥고를 종래의 기술로 다려먹는 방법 등의 불편을 개선하기 위하여 이러한 번거롭고 어려운 문제점을 해결하여 이를 쉽게 복용이 가능하도록 경옥고를 타정화하여 발표정으로 제형화함으로서 수시로 간편하게 복용이 가능하도록 할 수 있는 경옥고 또는 산양삼 추출물을 함유한 발포정의 제조방법 및 상기 경옥고 또는 산양삼 추출물을 대상으로 한 전자공여(DPPH) 활성 측정, SOD-like 활성 측정, Xanthine oxidase 저해활성 측정 등의 항산화활성 및 마우스의 CCRF 섬유아세포주을 이용한 함암작용 등과 같은 의학적 효능을 검증하여 본 발명을 완성하였다.
Therefore, this study solves these troublesome and difficult problems in order to improve the inconvenience of the conventional method of ironing jadeite with the conventional technology, and by quantifying the jadeite in order to make it easy to take it, it is easy to take it from time to time. Antioxidant activity such as preparation method of effervescent tablet containing jadeite or goat's ginseng extract and measurement of electron donation (DPPH) activity, measurement of SOD-like activity, measurement of Xanthine oxidase inhibitory activity, etc. The present invention was completed by verifying medical effects such as cancer-causing effects using CCRF fibroblast line of mice.
상기 목적을 달성하기 위해, In order to achieve the above object,
본 발명은 (1)비타민, 한약재 추출물 또는 경옥고, 유기산, 당알콜을 혼합하여 제 1혼합물을 얻고, 상기 제 1혼합물에 아미노산, 향료, 식염, 식품첨가물, 및 감미제로부터 선택된 하나 이상의 성분을 혼합하여 제 2혼합물을 얻는 제 1 단계; (2)상기 제 1혼합물 및 제 2 혼합물을 혼합한 다음에 상기 혼합물에 안정제를 첨가하여 혼합하는 제 2단계; (3)상기 제 2 단계의 안정제가 첨가된 혼합물에 결합제 및 발포제를 첨가하고 혼합하는 제 3 단계; (4) 상기 제 3 단계의 혼합물에 활택제, 붕해제, 착색제, 보존제를 각각 첨가하고 혼합하는 제 4 단계; (5) 상기 제 4단계의 혼합물을 타정하는 제 5단계 공정을 포함하는 경옥고 또는 산양삼 추출물을 함유한 발포정의 제조방법을 제공한다.The present invention is a mixture of (1) vitamins, herbal extracts or jadeite, organic acids, sugar alcohols to obtain a first mixture, by mixing one or more components selected from amino acids, flavors, salts, food additives, and sweeteners to the first mixture A first step of obtaining a mixture of two; (2) a second step of mixing the first mixture and the second mixture followed by adding a stabilizer to the mixture; (3) a third step of adding and mixing the binder and the blowing agent to the mixture to which the stabilizer of the second step is added; (4) a fourth step of adding and mixing a lubricant, a disintegrant, a colorant, and a preservative, respectively, to the mixture of the third step; (5) Provides a method for producing effervescent tablets containing jadeite or goat ginseng extract comprising the fifth step of the tableting the mixture of the fourth step.
보다 구체적으로는, 본 발명은 (1)비타민 2 내지 14 중량%, 바람직하게는 2 내지 10 중량%, 한약재 추출물 또는 경옥고 1 내지 18중량%, 바람직하게는 2 내지 10 중량%, 유기산 1 내지 14 중량%, 당알콜 1 내지 12중량%을 혼합하여 제 1혼합물을 얻고, 상기 제 1혼합물에 아미노산 0.5 내지 2중량%, 향료 6 내지 10중량%, 식염 0.2 내지 0.6중량%, 식품첨가물 1 내지 2중량%, 및 감미제 1 내지 2중량%를 혼합하여 제 2혼합물을 얻는 제 1단계; (2)상기 제 1혼합물 및 제 2 혼합물을 혼합한 다음에 상기 혼합물에 안정제 1 내지 12중량%을 첨가하여 혼합하는 제 2단계; (3)상기 (2)단계의 안정제가 첨가된 혼합물에 결합제 20 내지 40중량% 및 발포제를 4 내지 56 중량%, 바람직하게는 20 내지 30 중량%를 첨가하고 혼합하는 제 3 단계; (4) 상기 (3)단계의 혼합물에 활택제 1 내지 12중량%, 바람직하게는 1% 이하의 양 및 붕해제, 착색제 및 보존제를 합쳐 약 30 내지 90 중량%, 바람직하게는 50 내지 70 중량%를 첨가하고 혼합하는 제 4 단계; 상기 제 4단계의 혼합물을 타정하는 제 5단계 공정을 포함하는 경옥고 또는 산양삼 추출물을 함유한 발포정의 제조방법을 제공한다.More specifically, the present invention is (1) 2 to 14% by weight of vitamin, preferably 2 to 10% by weight, 1 to 18% by weight of herbal extract or jadeite, preferably 2 to 10% by weight,
상기 제조방법의 제 1 단계에서 상기 비타민은 수용성 비타민, 바람직하게는, 비타민 C, 또는 비타민 B1, 비타민 B2, 비타민 B6, 비타민 B12, 니코틴산아미드, 판토텐산, 비오틴, 엽산 중에서 선택된 어느 하나 이상의 비타민, 보다 바람직하게는 비타민 C임을 특징으로 한다.
In the first step of the manufacturing method, the vitamin is a water-soluble vitamin, preferably, vitamin C, or any one or more vitamins selected from vitamin B1, vitamin B2, vitamin B6, vitamin B12, nicotinamide, pantothenic acid, biotin, folic acid, and more. Preferably vitamin C.
상기 제조방법의 제 1 단계에서 피로회복 물질로 사용할 수 있는 상기 유기산은 구연산(citric acid), 사과산(maleic acid), 젖산(lactic acid), 주석산(tartaric acid), 호박산(succinic acid), 또는 푸마릭산(fumaric acid) 중에서 선택된 어느 하나 이상, 바람직하게는 구연산임을 특징으로 한다.
The organic acid that can be used as a fatigue recovery material in the first step of the production method is citric acid, maleic acid, lactic acid, tartaric acid, succinic acid, or puma At least one selected from fumaric acid, and preferably citric acid.
상기 제조방법의 제 1 단계에서 상기 한약재는 산양삼, 홍삼, 오가피, 오미자, 당귀, 구기자, 사상자, 복분자, 토사자, 천궁, 천마, 건강, 또는 대추이며; 상기 경옥고는 일정 배합비의 인삼, 하수오, 생지황, 복령, 지구목, 맥문동, 갈근 및 꿀, 바람직하게는 인삼 1 내지 6 중량%, 하수오 3 내지 15 중량%, 생지황 20 내지 40 중량%, 복령 2 내지 10 중량%, 지구목 10 내지 20 중량%, 맥문동 1 내지 6 중량%, 갈근 1 내지 10 중량% 및 꿀 10 내지 30 중량%의 조성으로 구성되는 경옥고 또는 산양삼 추출물은 추출물 분말 형태가 바람직하며, 상기 분말은 당해 기술 분야에서 통상적으로 사용되는 추출방법, 예를 들어, 열수를 이용한 열수추출법, 에탄올과 같은 용매를 이용한 용매추출법을 사용할 수 있다. In the first step of the manufacturing method, the herbal medicine is goat ginseng, red ginseng, ogapi, Schisandra chinensis, Angelica, Gugija, casualty, Bokbunja, Tosa, Cheongung, Cheonma, Health, or Jujube; The jadeite is a compounding ratio of ginseng, sewage, raw sulfur, Bokryeong, earth tree, ganmundong, brown root and honey, preferably
또는 선택적으로 상기 추출방법에 의해 추출한 추출물은 농축하여 20 내지 65 브릭스(brix), 바람직하게는 30 내지 45 브릭스(brix)의 농축물을 사용할 수 있다. 상기와 같은 추출방법으로 얻은 추출물은 타정하기에 용이한 분말 형태로 제형화하기 위해 동결건조 및 유동층건조 방법으로 건조하여 분말화할 수 있다. Alternatively, the extract extracted by the extraction method can be concentrated to use a concentrate of 20 to 65 brix, preferably 30 to 45 brix. Extract obtained by the extraction method as described above may be dried and powdered by lyophilization and fluidized bed drying method to formulate in a powder form that is easy to tablet.
상기에서 열수추출법 또는 용매추출법의 추출조건은 식품 또는 의약품 관련분야에서 널리 사용되는 조건을 이용하여 실시할 수 있다. 이러한 추출조건의 일예로서 60 내지 120℃, 바람직하게는 80 내지 100℃의 열수에서 10 내지 60분 동안 추출하는 열수추출법 또는 20 내지 80℃, 바람직하게는 40 내지 50℃의 물, 메탄올, 에탄올, 부탄올 또는는 이의 혼합용매로 10 내지 120분, 바람직하게는 30 내지 60분 동안 추출하는 용매추출법을 사용할 수 있다. 또한 열수추출법 또는 용매추출법을 이용하여 상기 생약으로부터 추출물을 얻은 후 이를 건조하는 건조조건의 일예로 -10℃ 내지 -60℃, 바람직하게는 -30℃ 내지 -40℃에서 동결건조, 또는 분무건조기를 이용한 분무건조를 실시하여 추출물을 분말화할 수 있다.Extraction conditions of the hot water extraction method or solvent extraction method may be carried out using conditions widely used in the food or pharmaceutical related fields. As an example of such extraction conditions, hot water extraction method which is extracted for 10 to 60 minutes in hot water of 60 to 120 ℃, preferably 80 to 100 ℃ or 20 to 80 ℃, preferably 40 to 50 ℃ water, methanol, ethanol, Butanol or a solvent extraction method may be used to extract for 10 to 120 minutes, preferably 30 to 60 minutes as a mixed solvent thereof. In addition, as an example of the drying conditions of obtaining the extract from the herbal medicine by using a hot water extraction method or a solvent extraction method and drying it, -10 ℃ to -60 ℃, preferably -30 ℃ to -40 ℃ freeze-drying, or spray dryer Extract may be powdered by performing spray drying.
본원에서 정의되는 한약재는 산양삼, 홍삼, 오가피, 오미자, 당귀, 구기자, 사상자, 복분자, 토사자, 천궁, 천마, 건강, 또는 대추임이며, 바람직하게는 산양삼 또는 경옥고를 포함한다.Herbal medicines as defined herein are goat's ginseng, red ginseng, ogapi, schisandra, Angelica, wolfberry, casualty, bokbunja, earth and sand, cheongung, cheonma, health, or jujube, and preferably goat or ginseng.
상기 제조방법의 제 1 단계에서 상기 제 1혼합물로서, 상기 당알콜은 감미를 나타내는 성분을 가지고 있으며, 통상적으로 사용하는 감미제와는 다른 특성을 가지고 있다. 일예로 당알콜은 산성 하에서 안정하여 pH 2∼10의 범위에서 변화가 없으며 용해도도 적당하고, 장내에서 난소화성을 나타내어 2.0∼2.4 kcal/g 정도의 저칼로리 물질로서 다양한 식품에 첨가되어 사용할 수 있다. 따라서 식품소재로서 저칼로리, 비만예방, 당뇨 환자용 설탕 대체 감미제로 널리 사용되고 있다. 본 발명에서 이러한 당알콜의 일예로서 만니톨 (mannitol), 솔비톨(sorbitol), 말티톨(maltito) 자일리톨(xylitol), 에리스리톨(Erythritol), 락티톨(lactitol), 글리시톨(glicitol), 리비톨(Ribitol), 갈락티톨(galactitol) 중에서 선택된 어느 하나 이상, 바람직하게는 D-소르비톨 또는 만니톨으로부터 선택된 하나 이상의 당알콜임을 특징으로 한다.
As the first mixture in the first step of the production method, the sugar alcohol has a component that exhibits sweetness, and has a characteristic different from that of a commonly used sweetener. For example, sugar alcohols are stable under acidic conditions, do not change in the range of
상기 제조방법의 제 1 단계에서 제 1혼합물에 선택적으로 아미노산, 향료, 식염, 식품첨가물, 및 감미제로부터 선택된 하나 이상의 성분을 제 2혼합물로 첨가가능하며, 바람직하게는, 아미노산 0.5∼2중량%, 향료 6∼10중량%, 식염 0.2∼0.6중량%, 식품첨가물 1∼2중량%, 및 감미제 1∼2중량%를 혼합하여 제 2혼합물을 제조가능하다.At least one component selected from amino acids, flavors, salts, food additives, and sweeteners may be optionally added to the first mixture in the first step of the preparation method as the second mixture, preferably, 0.5 to 2% by weight of amino acids, A second mixture can be produced by mixing 6 to 10% by weight of fragrance, 0.2 to 0.6% by weight of salt, 1 to 2% by weight of food additives, and 1 to 2% by weight of sweetener.
상기 제조공정의 상기 제 1 단계에서 제 2혼합물로서 첨가 가능한 피로회복 물질 또는 단백질 공급체로서 사용할 수 있는 아미노산, 예를 들어, 타우린(Taurine), 아스파틱산(Aspartic acid), 쓰레오닌(Threonine), 세린(Serine), 글루타믹산(Glutamic acid), 프롤린(Proline), 글리신(Glycine), 알라닌(Alanine), 시스테인(Cysteine), 발린(Valine), 메티오닌(Methionine), 이소류신(Isoleucine), 티로신(Tyrosine), 페닐알라닌(Phenylalanine), 트립토판(Tryptophane), 리신(Lysine), 히스티딘(Histidine), 아르기닌(Arginine) 중에서 선택된 어느 하나 이상을 사용할 수 있다.Amino acids, such as taurine, aspartic acid, threonine, which can be used as a fatigue recovery material or protein feeder that can be added as a second mixture in the first step of the manufacturing process , Serine, Glutamic acid, Proline, Glycine, Alanine, Cysteine, Valine, Methionine, Isoleucine, Tyrosine One or more selected from (Tyrosine), phenylalanine (Phenylalanine), tryptophane (Tryptophane), lysine (Lysine), histidine (Histidine), arginine (Arginine).
상기 제조공정의 상기 제 1 단계에서 제 2혼합물로서 첨가 가능한 향료로서는 발포정을 물에 용해시켜 섭취시 관능성을 향상시키기 위해 사용하는 향료는 식품학적으로 허용된 것이라면 어떠한 것이라도 사용할 수 있다. 본 발명에서 이러한 향료의 일예로서 파인애플향, 사과향, 오렌지향, 레몬향, 포도향, 체리향, 복숭아향, 살구향, 딸기향, 망고향, 라임향, 메론향, 매실향, 오디향, 복분자향, 인삼향, 홍삼향, 대추향, 생강향, 유자향 중에서 선택된 어느 하나 이상을 사용할 수 있다.As the fragrance which can be added as the second mixture in the first step of the manufacturing process, any of the fragrances used to dissolve the effervescent tablets in water to improve the organoleptic functionality can be used as long as they are food acceptable. As an example of the flavor in the present invention pineapple flavor, apple flavor, orange flavor, lemon flavor, grape flavor, cherry flavor, peach flavor, apricot flavor, strawberry flavor, mango flavor, lime flavor, melon flavor, plum flavor, mulberry flavor, bokbunja Incense, ginseng flavor, red ginseng flavor, jujube flavor, ginger flavor, citron flavor can be used any one or more selected.
상기 제조공정의 상기 제 1 단계에서 제 2혼합물로서 첨가 가능한 발포정에 적절한 염분을 함유하기 위해 첨가하는 식염은 종래 식품학적으로 사용할 수 있는 것이라면 어떠한 것이라도 사용할 수 있다. 본 발명에서 이러한 식염의 일예로서 염화칼륨(Potassium Chloride, KCl), 염화나트륨(NaCl) 중에서 선택된 어느 하나 이상을 사용할 수 있다.The salt added in order to contain a suitable salt in the effervescent tablet which can be added as a 2nd mixture in the said 1st step of the said manufacturing process can be used as long as it can be used conventionally in food science. In the present invention, as one example of such a salt, any one or more selected from potassium chloride (Potassium Chloride, KCl) and sodium chloride (NaCl) may be used.
상기 제조공정의 상기 제 1 단계에서 제 2혼합물로서 첨가 가능한 발포정에 관능성을 향상시키기 위해 첨가하는 식품첨가물은 종래 식품학적으로 사용할 수 있는 것이라면 어떠한 것이라도 사용할 수 있다. 본 발명에서 이러한 식품첨가물의 일예로서 글루콘산 나트륨(Sodium Gluconate, C 6 H 11O 7 Na)을 사용할 수 있다.Food additives added to improve the functionality of the foamed tablets that can be added as the second mixture in the first step of the manufacturing process can be used as long as they can be used conventionally in food science. As an example of such a food additive in the present invention, sodium gluconate (C 6 H 11 O 7 Na) may be used.
상기 제조공정의 상기 제 1 단계에서 제 2혼합물로서 첨가 가능한 발포정이 맛에 대한 관능성을 향상시키기 위해 첨가하는 감미제는 식품학적으로 사용할 수 있는 것이라면 어떠한 것이라도 사용할 수 있다. 본 발명에서 이러한 감미제의 일예로서 아스파탐, 설탕, 사카린, 아세설팜칼륨, 스테비오사이드, 포도당, 과당, 설탕 중에서 선택된 어느 하나 이상을 사용할 수 있다.In the first step of the manufacturing process, the sweetening agent added as a second mixture in order to improve the functionality of taste can be used as long as it can be used in food. As an example of such a sweetener in the present invention, any one or more selected from aspartame, sugar, saccharin, acesulfame potassium, stevioside, glucose, fructose and sugar may be used.
본 발명에서 발포정을 제조함에 있어서, 본 발명의 목적하는 바를 이루기 위해 (1)공정에서 제 1혼합물을 먼저 얻고, 재차 (1)공정에서 제 2혼합물을 얻은 다음 각각의 혼합물을 혼합하는 것이 좋다. 이때 본 발명의 목적에 부합하는 발포정을 제조하기 위해 (1)공정에서 다양한 함량에 대해 비타민, 허브추출물 분말, 유기산 및 당알콜을 혼합한바 비타민 3∼4중량%, 허브추출물 분말 1∼2중량%, 유기산 36.4∼57.3중량%, 당알콜 4∼6중량%을 혼합하여 제 1혼합물을 얻는 것이 좋다. 또한 제(1)공정에서 다양한 함량에 대해 아미노산, 향료, 식염, 식품첨가물, 감미제를 혼합한바, 아미노산 0.5 내지 2중량%, 향료 6 내지 10중량%, 식염 0.2 내지 0.6중량%, 식품첨가물 1 내지 2중량%, 감미제 1 내지 2중량%를 혼합하여 제 2혼합물을 얻는 것이 좋다.In preparing the foamed tablet in the present invention, in order to achieve the object of the present invention, it is preferable to first obtain the first mixture in the step (1), and then obtain the second mixture in the step (1) and then mix the respective mixtures. . At this time, in order to produce effervescent tablets according to the object of the present invention (1) in the step of vitamins, herbal extract powder, organic acid and sugar alcohols mixed in various contents bar vitamin 3-4% by weight, herbal extract powder 1-2% by weight , 36.4 to 57.3% by weight of organic acid, and 4 to 6% by weight of sugar alcohol may be mixed to obtain a first mixture. In addition, amino acids, flavors, salts, food additives, and sweeteners are mixed with respect to various contents in step (1), and 0.5 to 2% by weight of amino acids, 6 to 10% by weight of flavors, 0.2 to 0.6% by weight of salts, and
상기 제조공정의 상기 제 2 단계에서 (1) 단계의 제 1혼합물 및 제2혼합물을 혼합한 다음에 이 혼합물에 식품제조에 사용할 수 있는 안정제를 1 내지 20중량%, 바람직하게는, 2 내지 10 중량% 양으로 첨가하여 혼합물을 안정화시킨다. 상기 (2)공정에서 안정제를 전술한 수치 범위 미만으로 사용하면 안정제를 사용하는 의미가 없으며, 안정제를 전술한 수치 범위 초과하여 사용하면 발포정이 물속에서 용해되는 시간이 증가할 우려가 있다. 따라서 상기 (2)공정에서 안정제는 전술한 수치 범위 이내에서 사용하는 것이 좋다. 상기 (2)공정에서 사용하는 안정제는 식품학적으로 사용할 수 있는 것이라면 어떠한 것이라도 사용할 수 있다. 본 발명에서 이러한 안정제의 일예로서 식품제조시 안정제로 사용할 수 있으며, 물에 대한 용해도가 좋은 제삼인산칼슘, 제일인산칼슘, 주석산나트륨(Sodium Tartrate), 푸마르산나트륨(Mono Sodium Fumarate) 또는 D-L 말산 중에서 선택된 어느 하나 이상, 바람직하게는 제삼인산칼슘, 또는 제일인산칼슘 중에서 선택된 어느 하나 이상을 사용할 수 있다.
1 to 20% by weight, preferably 2 to 10, of a stabilizer which can be used for food preparation after mixing the first mixture and the second mixture of step (1) in the second step of the manufacturing process. Addition in weight percent amounts to stabilize the mixture. In the step (2), if the stabilizer is used below the above-mentioned numerical range, there is no meaning of using the stabilizer. If the stabilizer is used above the above-mentioned numerical range, there is a concern that the time for dissolving the expanded tablet in water may increase. Therefore, the stabilizer in the step (2) is preferably used within the above-described numerical range. The stabilizer used in the step (2) can be used as long as it can be used in food. As an example of such a stabilizer in the present invention, it can be used as a stabilizer in food production, selected from among tricalcium phosphate, calcium phosphate, sodium tartrate, sodium fumarate or DL malic acid with good solubility in water. Any one or more, preferably any one or more selected from tricalcium phosphate or monobasic calcium phosphate can be used.
상기 제조공정의 제 3 단계에서 본원에서 사용가능한 결합제는 10 내지 60중량%, 바람직하게는, 2 내지 40 중량% 양으로 첨가가능하며, 당업계에 통상적인 결합제로서는 바람직하게는 유당, CMC-Ca, 물, 유기용매, 폴리비닐피롤리돈, 히드록시프로필셀룰로오스, 미결정셀룰로오스, 히드록시프로필메틸셀룰로오스, 덱스트린, 젤라틴, 메틸셀룰로오스, 히드록시셀룰로오스,히드록시메틸셀룰로오스, 폴리비닐알콜, 예비-젤라틴화된 전분(Pregelatinized Starch) 또는 아라비아 검으로부터 선택되는 1종 이상, 바람직하게는 유당, CMC-Ca으로부터 선택되는 1종 이상의 성분을 추가로 포함할 수 있으며, The binder usable in the third step of the manufacturing process can be added in an amount of 10 to 60% by weight, preferably 2 to 40% by weight, and as binders conventional in the art, preferably lactose, CMC-Ca , Water, organic solvent, polyvinylpyrrolidone, hydroxypropylcellulose, microcrystalline cellulose, hydroxypropylmethylcellulose, dextrin, gelatin, methylcellulose, hydroxycellulose, hydroxymethylcellulose, polyvinyl alcohol, pre-gelatinized It may further comprise at least one component selected from starch (Pregelatinized Starch) or gum arabic, preferably at least one component selected from lactose, CMC-Ca,
상기 제조공정의 제 3단계에서 제 2 단계에 의해 안정제가 첨가된 혼합물에 발포제를 1 내지 20중량%, 바람직하게는, 2 내지 15 중량% 양으로 첨가하고 혼합하여 발포정이 물속에서 용해되는 발포성을 갖도록 할 수 있다. 상기 (3)공정에서 발포제를 전술한 수치 범위 미만으로 사용하면 발포제를 사용하는 의미가 없으며, 발포제를 전술한 수치 범위 초과하여 사용하면 발포정이 물에서 용해될 때 용해되는 시간이 오래 소요되는 문제가 있다. 따라서 상기 (3)공정에서 발포제는 전술한 수치 범위 이내에서 사용하는 것이 좋다. 상기 (3)공정에서 사용하는 발포제는 식품학적으로 사용할 수 있는 것이라면 어떠한 것이라도 사용할 수 있다. 본 발명에서 이러한 발포제의 일예로서 탄산수소나트륨, 중탄산나트륨(Sodium Bicarbonate, NaHCO 3 )으로부터 선택되는 1종 이상의 성분을 사용할 수 있다.Foaming property in which the foaming tablet is dissolved in water by adding and mixing the blowing agent in an amount of 1 to 20% by weight, preferably 2 to 15% by weight, to the mixture to which the stabilizer is added in the third step to the second step of the manufacturing process. You can have it. In the step (3), if the blowing agent is used below the above-mentioned numerical range, there is no meaning of using the blowing agent, and if the blowing agent is used above the above-mentioned numerical range, there is a problem that it takes a long time to dissolve when the foaming tablet is dissolved in water. have. Therefore, the blowing agent in the step (3) is preferably used within the above-described numerical range. The foaming agent used in the above (3) step can be used as long as it can be used in food. As an example of such a blowing agent in the present invention, one or more components selected from sodium bicarbonate and sodium bicarbonate (NaHCO 3) may be used.
상기 제조공정의 제 4 단계에서 본원에서 사용가능한 활택제로는 1 내지 5중량%, 바람직하게는, 1 내지 3 중량% 양으로 첨가하고, 통상의 활택제로서 바람직하게는 스테아린산 마그네슘(Mg Stearate), 탈크, 스테아린산 또는 무수경질규산(SiO2)으로 이루어진 1종 이상의 혼합물을 사용할 수 있으며,In the fourth step of the manufacturing process, the lubricant used in the present application may be added in an amount of 1 to 5% by weight, preferably 1 to 3% by weight, and as a conventional lubricant, preferably magnesium stearate, Mg Stearate, One or more mixtures of talc, stearic acid or light silicic anhydride (SiO 2 ) may be used,
상기 제조공정의 제 4 단계에서 선택적으로 당업계에 통상적인 붕해제, 착색제, 보존제 성분을 1종 이상 추가로 각각 1 내지 50중량%, 바람직하게는, 1 내지 30중량% 양으로 혼합가능하고 이외에도 향미제, 안정화제, 또는 희석제를 추가로 함유할 수 있다.In the fourth step of the manufacturing process, optional disintegrant, colorant, and preservative components conventionally known in the art may be mixed in an amount of 1 to 50% by weight, preferably 1 to 30% by weight, respectively. It may further contain a flavourant, stabilizer, or diluent.
본원에서 사용가능한 붕해제로는 통상의 붕해제로서 바람직하게는 전분글리콜레이트나트륨, 크로스포비돈(Crospovidone), 크로스카르복시메틸셀룰로오스소듐염(Cross-linked sodium carboxymethyl cellulose), 저치환히드록시프로필셀룰로오스(LowSubstituted Hydroxypropylcellulose), 히드록시프로필메틸셀룰로오스, 폴리비닐피롤리돈, 전분, 카복시메틸셀룰로오스칼슘 및 이들의 조합으로 이루어진 1종 이상을 포함할 수 있으며,Disintegrants usable herein include, as conventional disintegrants, sodium starch glycolate, crospovidone, cross-linked sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose. Hydroxypropylcellulose), hydroxypropylmethylcellulose, polyvinylpyrrolidone, starch, carboxymethyl cellulose calcium and combinations thereof, and may include one or more thereof.
또한, 필요한 경우, 착색제를 정제에 포함시킬 수 있으며, 이산화티탄, 산화철, 탄산마그네슘, 황산칼슘, 산화마그네슘, 수산화마그네슘 또는 알루미늄레이크 (aluminium lake)등에서 선택된 1종 이상을 포함할 수 있으며, In addition, if necessary, a colorant may be included in the tablet, and may include one or more selected from titanium dioxide, iron oxide, magnesium carbonate, calcium sulfate, magnesium oxide, magnesium hydroxide, aluminum lake, and the like.
본원에서 사용가능한 보존제로는 벤조인산, 메틸파라벤, 에틸파라벤 또는 프로필파라벤 등에서 선택된 1종 이상이 첨가가능하다.
Preservatives usable herein may include one or more selected from benzoic acid, methylparaben, ethylparaben or propylparaben and the like.
상기 (4)공정에서 제 3 단계에 의해 발포제가 첨가되어 발포정 조성물이 혼합된 혼합물은 타정기를 이용하여 타정함으로써 발포정을 제조할 수 있다. 이때 발포제를 포함하는 발포정 조성물을 타정시 타정 조건은 종래 일반적으로 발포정 제조시 사용하는 조건을 이용하여 발포정을 제조할 수 있다. 이러한 타정 조건의 이때 발포제를 포함하는 발포정 조성물을 타정시 타정 조건은 종래 일반적으로 발포정 제조시 사용하는 조건을 이용하여 발포정을 제조할 수 있다. 이러한 타정 조건의 일예로서 온도 22∼24℃, 상대습도 10∼30%에서 단발타정기와 같은 타정기로 타정하여 발포정을 얻을 수 있다.In the step (4), the mixture in which the blowing agent is added in the third step and the foaming tablet composition is mixed can be prepared by tableting using a tableting machine. At this time, when tableting the foamed tablet composition including the foaming agent, the tableting conditions may be prepared using the conditions generally used in manufacturing foamed tablets. At the time of such tableting conditions, the tableting conditions for tableting the foamed tablet composition including the foaming agent may be prepared using the conditions generally used in manufacturing foamed tablets. As an example of such tableting conditions, a foamed tablet can be obtained by tableting with a tableting machine such as a single tableting machine at a temperature of 22 to 24 ° C and a relative humidity of 10 to 30%.
상기에서 언급한 목적을 달성하기 위한 본 발명의 발포정의 제조방법은 피로회복 물질을 주재료로 하고, 식품학적으로 허용된 부형제를 부재료로 하여 얻을 수 있다. 이때 피로회복 물질의 일예로서 비타민, 한방허브추출물 분말, 유기산 및 아미노산을 사용할 수 있고, 나머지 부형제로서 식품학적으로 사용이 허용된 식품첨가물, 안정제, 감미제, 당알콜, 식염, 향료, 발포제를 사용할 수 있다.
The method for producing the expanded tablet of the present invention for achieving the above-mentioned object can be obtained by using the fatigue recovery material as a main material, and the food-acceptable excipient as a subsidiary material. In this case, as an example of the fatigue recovery material, vitamins, herbal herb extract powders, organic acids and amino acids may be used, and as the other excipients, food additives, stabilizers, sweeteners, sugar alcohols, salts, flavorings, and foaming agents allowed to be used in foods may be used. .
또한 본원 발명은 상기 제조방법으로 제조된 항산화활성 및 항암 활성이 탁월한 발포정 제제를 제공한다.In another aspect, the present invention provides an effervescent tablet preparation excellent in antioxidant activity and anticancer activity prepared by the above production method.
본 발명의 조성물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다.The preferred dosage of the composition of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the type of drug, the route of administration and the period of time, but can be appropriately selected by those skilled in the art.
따라서, 본 발명은 상기의 제조방법으로 얻어진 한약재 추출물 또는 경옥고를 유효성분으로 함유하는 항산화 및 암질환의 예방 및 치료용 약학제제를 제공한다.Accordingly, the present invention provides a pharmaceutical preparation for the prevention and treatment of antioxidant and cancer diseases, which contains the herb extract or jadeite as an active ingredient.
본 발명의 약학 조성물은 조성물 총 중량에 대하여 상기 추출물을 0.1 내지 50 중량%로 포함한다.The pharmaceutical composition of the present invention comprises 0.1 to 50% by weight of the above extract, based on the total weight of the composition.
그러나 상기와 같은 조성은 반드시 이에 한정되는 것은 아니고, 환자의 상태 및 질환의 종류 및 진행 정도에 따라 변할 수 있다.However, the composition is not limited thereto, and may vary depending on the condition of the patient, the type of disease, and the progress of the disease.
본 발명의 추출물 자체는 독성 및 부작용이 거의 없으므로 예방 목적으로 장기간 복용 시에도 안심하고 사용할 수 있는 약제이다. Since the extract of the present invention has little toxicity and side effects, it can be safely used even for long-term administration for the purpose of prevention.
본 발명의 조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.The compositions of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions.
본 발명의 조성물은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있으며, 추출물을 포함하는 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜 (propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.The composition of the present invention may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterilized injection solutions, Examples of carriers, excipients and diluents that can be included in the composition containing the extract include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate , Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid preparations may include at least one excipient such as starch, calcium carbonate, sucrose in the extract. ) Or lactose, gelatin and the like are mixed. In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of suppository bases include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like.
본 발명의 조성물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나 바람직한 효과를 위해서, 본 발명의 추출물은 1일 0.5 g/kg 내지 5 g/kg으로, 바람직하게는 1 g/kg 내지 3 g/kg으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수 있다. 따라서, 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The preferred dosage of the composition of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the type of drug, the route of administration and the period of time, but can be appropriately selected by those skilled in the art. However, for the desired effect, the extract of the present invention is preferably administered at 0.5 g / kg to 5 g / kg, preferably 1 g / kg to 3 g / kg per day. The administration may be carried out once a day or divided into several doses. Thus, the dosage amounts are not intended to limit the scope of the invention in any manner.
본 발명의 조성물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관내 (intracerebroventricular) 주사에 의해 투여될 수 있다.
The composition of the present invention may be administered to mammals such as rats, mice, livestock, humans, and the like in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine or intracerebroventricular injections.
또한, 본 발명은 상기의 제조방법으로 얻어진 한약재 추출물 또는 경옥고를 유효성분으로 함유하는 항산화 및 암질환의 예방 및 개선용 건강기능식품을 제공한다. In addition, the present invention provides a health functional food for the prevention and improvement of antioxidant and cancer diseases containing the herbal extract or jadeite as an active ingredient obtained by the above production method.
본원에서 정의되는 "건강기능식품"은 건강기능식품에 관한 법률 제6727호에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 의미하며, "기능성"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다.&Quot; Health functional food "as defined herein means food prepared and processed using raw materials or ingredients having functionality useful to the human body in accordance with Law No. 6727 on Health Functional Foods." Functional " Structure and function of the nutrient to control or physiological effects, such as to obtain a beneficial effect for health is intended to eat.
본 발명의 항산화 및 암 예방을 위한 건강기능식품은, 조성물 총 중량에 대하여 상기 추출물을 0.01 내지 95 %, 바람직하게는 1 내지 80 % 중량백분율로 포함한다.The dietary supplement for antioxidant and cancer prevention of the present invention comprises the extract in an amount of 0.01 to 95%, preferably 1 to 80% by weight, based on the total weight of the composition.
또한, 비만증 예방을 위한 목적으로 정제, 캅셀, 분말, 과립, 액상, 환 등의 형태인 건강기능식품으로 제조 및 가공이 가능하다.In addition, it is possible to manufacture and process as a dietary supplement in the form of tablets, capsules, powders, granules, liquid, pills for the purpose of preventing obesity.
본 발명은 항산화 및 암의 예방 및 치료의 효과를 나타내는 상기 한약재 추출물 또는 경옥고를 포함하는 건강보조식품을 제공한다. 상기 추출물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강 기능성 식품류 등이 있다.The present invention provides a dietary supplement comprising the above-mentioned herbal extract or jadeite ointment showing the effects of antioxidant and cancer prevention and treatment. Examples of foods to which the extract can be added include various foods, beverages, gums, tea, vitamin complexes, and health functional foods.
본 발명의 추출물을 포함하는 조성물은 항산화 및 암의 예방 및 개선을 위한 약제, 식품 및 음료 등에 다양하게 이용될 수 있다. 본 발명의 추출물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강보조 식품류 등이 있고, 분말, 과립, 정제, 캡슐 또는 음료인 형태로 사용할 수 있다.The composition containing the extract of the present invention can be used in various ways, such as drugs, foods and drinks for the prevention and improvement of antioxidants and cancer. Examples of the foods to which the extract of the present invention can be added include various foods, beverages, gums, tea, vitamin complexes, health supplements and the like, and they can be used as powders, granules, tablets, capsules or beverages have.
또한, 본 발명은 항산화 활성 및 항암활성을 갖는 상기의 제조방법으로 얻어진 한약재 추출물 또는 경옥고를 유효성분으로 함유하는 식품첨가제를 제공한다. 본 발명의 추출물은 암질환의 예방 및 개선을 목적으로 식품 또는 음료에 첨가될 수 있다. 이 때, 식품 또는 음료 중의 상기 추출물의 양은 일반적으로 본 발명의 건강식품 조성물은 전체 식품 중량의 1 내지 5 중량%로 가할 수 있으며, 건강 음료 조성물은 100 ㎖를 기준으로 0.02 내지 10 g, 바람직하게는 0.3 내지 1 g의 비율로 가할 수 있다. In another aspect, the present invention provides a food additive containing an herbal extract or jadeite as an active ingredient obtained by the above production method having antioxidant activity and anticancer activity. Extract of the present invention may be added to food or beverage for the purpose of preventing and improving cancer diseases. At this time, the amount of the extract in the food or beverage is generally the health food composition of the present invention can be added to 1 to 5% by weight of the total food weight, the health beverage composition is 0.02 to 10 g, preferably based on 100 ml Can be added in a ratio of 0.3 to 1 g.
본 발명의 건강 음료 조성물은 지시된 비율로 필수 성분으로서 추출물을 함유하는 것 외에 액체성분에는 특별한 제한점은 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등의 디사카라이드, 예를 들어 말토스, 수크로스 등의 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등)) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 1 내지 20g, 바람직하게는 약 5 내지 12g이다.The health beverage composition of the present invention, in addition to containing the extract as an essential ingredient in the indicated ratio, there is no particular limitation on the liquid component and may contain various flavors or natural carbohydrates, etc. as additional ingredients, like ordinary drinks. Examples of the above-mentioned natural carbohydrates are conventional monosaccharides such as disaccharides such as glucose and fructose, such as maltose, sucrose and the like, and polysaccharides such as dextrin, cyclodextrin and the like. Sugars and sugar alcohols such as xylitol, sorbitol, and erythritol. As natural flavors other than those described above, natural flavors (such as tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin)) and synthetic flavors (saccharin, aspartame, etc.) have. The proportion of such natural carbohydrates is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 조성물들은 천연 과일 쥬스 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.
In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and its Salts, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, and the like. In addition, the compositions of the present invention may contain flesh for the production of natural fruit juices and vegetable beverages. These components may be used independently or in combination. The proportion of such additives is not so critical, but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.
상기에서 설명한 바와 같이, 본 발명의 경옥고 또는 산양삼 추출물을 함유한 발포정은 수시로 간편하게 복용이 가능하도록 할 수 있으며 상기 경옥고 또는 산양삼 추출물을 대상으로 한 전자공여(DPPH) 활성 측정, SOD-like 활성 측정, Xanthine oxidase 저해활성 측정 등의 항산화활성 및 마우스의 CCRF 섬유아세포주을 이용한 함암작용 등에서 우수환 의학적 효능이 검증되어 의약품 및 건강기능식품 등의 조성물 및 제형으로 유용하게 이용할 수 있다.
As described above, effervescent tablets containing jadeite or goat's ginseng extract of the present invention can be easily taken at any time, and measuring the electron donation (DPPH) activity of the jadeite or goat's ginseng extract, SOD-like activity measurement, The excellent medicinal efficacy has been proven in antioxidant activity such as Xanthine oxidase inhibitory activity measurement and anticancer activity using CCRF fibroblast line of mouse, and can be usefully used as a composition and formulation of medicines and health functional foods.
도 1은 경옥고 추출물의 세포생존율 측정 실험결과를 나타낸 도이며;
도 2은 산양삼 추출물의 세포생존율 측정 실험결과를 나타낸 도이며;
도 3는 개개 추출물의 DPPH 라디칼 소거 활성을 측정한 실험결과를 나타낸 도이며;
도 4는 개개 추출물의 SOD 유사 활성을 측정한 실험결과를 나타낸 도이며;
도 5는 개개 추출물의 크산틴 옥시다제(Xanthine oxidase) 저해 활성을 측정한 실험결과를 나타낸 도이며;
도 6는 발포정의 발포효과를 확인한 실험 결과를 나타낸 도이다. 1 is a diagram showing the results of experiments measuring the cell viability of jadeite extract;
Figure 2 is a diagram showing the results of the cell survival rate measurement of goat ginseng extract;
Figure 3 is a diagram showing the experimental results of measuring the DPPH radical scavenging activity of the individual extracts;
4 is a diagram showing the results of experiments measuring the SOD-like activity of the individual extracts;
5 is a diagram showing the results of experiments measuring the xanthine oxidase inhibitory activity of the individual extracts;
6 is a view showing an experimental result confirming the foaming effect of the foamed tablets.
이하, 본 발명을 하기 참고예 및 실험예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail with reference to the following Reference Examples and Experimental Examples.
단, 하기 참고예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 참고예 및 실험예에 의해 한정되는 것은 아니다.
However, the following Reference Examples and Experimental Examples are merely illustrative of the present invention, and the content of the present invention is not limited by the following Reference Examples and Experimental Examples.
참고예Reference Example 1. One. 경옥고Jadeite 추출물의 제조 Preparation of extract
실험에 사용된 경옥고는 대구약령시에서 한약재를 구입하였으며 경옥고는 하기 표 1의 조성으로 제조된 (주)약령시사람들(www.w-herbmall.com)을 구입하여 사용하였다.The jadeite used in the experiment was purchased with herbal medicine in Daegu Yangnyeongsi, and the jadeite purchased (Yangnyeongsi Co., Ltd.) ( www.w-herbmall.com ) manufactured with the composition of Table 1 was used.
상기에서 제조된 경옥고를 물에 녹인 후 12,000 rpm으로 원심분리기(Centrifuge continental R 및 Hanil Science Industrial Co., Ltd.)로 원심분리한 후 침전액은 버리고 상등액을 0.8㎛ membrane filter(DISMIC -25CS, Advantec )를 이용하여 여과한 후에 동결건조기(10-RT, ilshin Lab Co., Ltd.) 및 유동층과립건조기(TIM-G30, Jaeilkigong)로 동결건조하여 얻은 분말(이하 KOG라 함)을 이용하여 하기 실험예에 사용하였다.
After dissolving the prepared jadeite in water and centrifuging with a centrifuge (Centrifuge continental R and Hanil Science Industrial Co., Ltd.) at 12,000 rpm, the precipitate is discarded and the supernatant is 0.8 μm membrane filter (DISMIC). The powder obtained by lyophilization with lyophilizer (10-RT, ilshin Lab Co., Ltd.) and fluidized bed granulator (TIM-G30, Jaeilkigong) after filtration using -25CS, Advantec) It was used in the following experimental example.
참고예Reference Example 2. 2. 산양삼Goat's ginseng 추출물의 제조 Preparation of extract
실험에 사용된 산양삼은 8년근(대구약령시)으로 물로 100 ℃에서 4시간 환류 추출한 추출물을 여과 및 농축한 후에, 12,000 rpm으로 원심분리기(Centrifuge continental R 및 Hanil Science Industrial Co., Ltd.)로 원심분리한 후 침전액은 버리고 상등액을 0.8㎛ membrane filter(DISMIC -25CS, Advantec )를 이용하여 여과한 후에 동결건조기(10-RT, ilshin Lab Co., Ltd.) 및 유동층과립건조기(TIM-G30, Jaeilkigong)로 동결건조하여 얻은 분말(이하 SYS라 함)을 이용하여 하기 실험예에 사용하였다.
Goat ginseng used in the experiment was filtered for 8 years and extracted with reflux extracted at 100 ° C for 4 hours with water for 8 years (Daegu Yangnyeongsi), and then centrifuged at 12,000 rpm with centrifuge continental R and Hanil Science Industrial Co., Ltd. After separation, discard the precipitate and filter the supernatant with a 0.8㎛ membrane filter (DISMIC). The powder obtained by lyophilization with lyophilizer (10-RT, ilshin Lab Co., Ltd.) and fluidized bed granulator (TIM-G30, Jaeilkigong) after filtration using -25CS, Advantec) It was used in the following experimental example.
실시예Example 1. One. 발포정Effervescent tablet 제조 Produce
하기의 공정을 이용하여 비타민을 포함하는 발포정을 제조하였다.Effervescent tablets containing vitamins were prepared using the following procedure.
(1)비타민 C 8.0중량%, 생약추출물 2.0중량%, 구연산 7.5중량%, 만니톨 6.0중량%를 혼합하여 제1혼합물을 얻었다. 또한 제1혼합물과는 별도로 감미제로서 D-소르비톨 1.0중량%, 만니톨 6.0중량%를 혼합하여 제2혼합물을 얻었다.(1) 8.0% by weight of vitamin C, 2.0% by weight of herbal extract, 7.5% by weight of citric acid and 6.0% by weight of mannitol were mixed to obtain a first mixture. In addition to the first mixture, 1.0% by weight of D-sorbitol and 6.0% by weight of mannitol were mixed as a sweetener to obtain a second mixture.
(2)상기 제1혼합물 및 제2혼합물을 혼합한 다음 이 혼합물에 안정제로써 제삼인산칼슘 1.0중량%, 제일인산칼슘 1.0중량%를 혼합하였다.(2) After mixing the first mixture and the second mixture, 1.0% by weight of tricalcium phosphate and 1.0% by weight of monobasic calcium phosphate were mixed as a stabilizer.
(3)상기 (2)단계에 의해 안정제가 첨가된 혼합물에 결합제로서 유당 30.0중량%, CMC-Ca 2.0중량%, 발포제로써 탄산수소나트륨 10.0중량%를 첨가한 다음 혼합하였다.(3) 30.0% by weight of lactose, 2.0% by weight of CMC-Ca, and 10.0% by weight of sodium hydrogencarbonate as a blowing agent were added to the mixture to which the stabilizer was added in step (2), followed by mixing.
(4)상기 (3)단계에 의해 발포제가 첨가된 혼합물에 활택제로서 스테아린산마그네슘 1.5중량%를 첨가한 다음 혼합하였다.(4) 1.5 wt% of magnesium stearate as a lubricant was added to the mixture to which the blowing agent was added in the step (3), followed by mixing.
(5)상기 혼합물을 온도 20℃, 상대습도 30%에서 로타리 타정기로 타정하여 중량이 2,000mg 이고, 지름 1.8cm, 두께가 6mm인 원형의 발포정을 제조하였다.(5) The mixture was compressed into tablets using a rotary tablet press at a temperature of 20 ° C. and a relative humidity of 30% to prepare circular foamed tablets having a weight of 2,000 mg, a diameter of 1.8 cm, and a thickness of 6 mm.
상기에서 생약추출물 분말은 생약 수종을 100℃에서 180분 동안 추출하고 30브릭스(brix)가 되도록 농축한 다음 동결건조하여 얻었다. 한편, 발포정 조성성분 및 함량을 아래의 표 2에 정리하여 나타내었다.The herbal extract powder was obtained by extracting the herbal extracts for 180 minutes at 100 ℃ and concentrated to 30 brix (brix) and then lyophilized. On the other hand, the foamed tablet composition and content are shown in Table 2 below.
마그네슘Stearic acid
magnesium
셀룰로오스칼슘Carboxymethyl
Cellulose calcium
(우유/미국산),
덱스트린 5%Lactose 95%
(Milk / U.S.),
Dextrin 5%
(KOG)Herbal Extract
(KOG)
상기 실험결과, 주원료 최소 함량(Vit C, 건기식 적합 기준)으로 기준용량을 계산 및 선택한 결과, (1) 비타민, 추출분말은 10% 이하로 배합하고, (2) 유기산은 첨가 범위를 넓게 가능하고 , (3) 발포제는 20~25%가 적당하며, (4) 탄산염 이외의 결합제, 붕해제, 활택제는 50~ 70% 정도 배합이 가능하며, (5) 활택제로서는 스테아린산마그네슘 극미량 혹은 안식향산나트륨 1% 이하로 배합함이 적당하며, (6) 함습을 잡아주는 전분류를 5~20% 정도 넣으면 좋으며, (7) MC 결정셀룰로오스는 타정에는 좋으나 많을수록 탁하고 슬러지 심하므로 1% 내지 20%범위로 첨가함이 바람직하며, (7) 기타 불용성 불순물은 물 용해도의 확인시에 필요하고, 불순물이 뜨는지 여부 및 동결추출분말이 녹은 후에 슬러지 여부를 확인할 필요가 있음을 확인하였다.
The experimental results, the main ingredient not less than (Vit C, suitable reference geongisik) as result a reference capacitance calculation and selected, (1) vitamins, extract powder is blended with 10% or less, (2) organic acids, and can broaden the addition range , (3) 20 to 25% of foaming agent is suitable, (4) 50 to 70% of binder, disintegrant, and lubricant other than carbonate can be blended. (5) Very small amount of magnesium stearate or sodium benzoate as lubricant. It is suitable to mix it with 1% or less, (6) It is good to add about 5 ~ 20% of starch that holds moisture, and (7) MC crystalline cellulose is good for tableting, but the more turbid and sludge, the more 1% ~ 20% range (7) It was confirmed that it is necessary to confirm that the other insoluble impurities are necessary for checking the water solubility, and whether or not the impurities float and the sludge after the frozen extract powder is dissolved.
실험예 1. 경옥고 및 산양삼 추출물의 항암 활성 검증Experimental Example 1. Validation of anticancer activity of Kyongokgo and Goatsam extract
상기 실시예에서 얻은 시료의 항암활성을 확인하기 위하여 문헌에 기재된 방법을 응용하여 하기와 같이 실험을 수행하였다(Ishiyama M. etal, 1996. Bio Pharm Bull 19: 1518-1520).
In order to confirm the anticancer activity of the sample obtained in the above example, the experiment was performed by applying the method described in the literature (Ishiyama M. etal, 1996. Bio Pharm Bull 19: 1518-1520).
1.1. 세포배양1.1. Cell culture
마우스의 CCRF 섬유아세포주는 한국세포주은행 으로 부터 분양 받아 배양하였으며 5% 불활성화시킨 FBS(fetal bovine serum), 젠타마이신(gentamicin) 50 ㎍/㎖를 첨가한 DMEM 배지(Dulbecco's modified Eagle's medium)에서 37℃, 5%의 CO2 배양기에서 배양하였다.
CCRF fibroblasts from mice were cultured from Korea Cell Line Bank and cultured at 37 ° C in DMEM medium (Dulbecco's modified Eagle's medium) containing 50 ㎍ / ml of FBS (gentamicin) and 5% inactivated FBS (fetal bovine serum). , 5% CO 2 incubator.
1.2. 세포 생존력 측정1.2. Cell viability measurement
마우스의 CCRF 섬유아세포를 배양하여 96 well plate에 8 X 104 cells/ml로 같은 수로 분주한 후에 안정화시키고 각각의 경옥고 처방제와 삼양삼추출액을 열수 및 EtOH 추출한 후, 농축하여 동결건조한 파우더를 0.1~ 10mg/ml 농도로 처리하고 24시간 배양 한 후 배양액을 제거하고, MTT 시약 (3-[4,5-dimethylthiazol-2- yl]-2,5-diphenyltetrazolium bromide; 0.5 mg/ml)을 30 μl씩 넣어주고, 3시간 동안 37℃ CO2 배양기에서 반응시킨다. 이렇게 생성된 불용성 포마잔 결정을 dimethylsulfoxide(DMSO) 100μl를 넣어 녹여주고 microplate reader(Sunrise Basic Tecan, TECAN)를 이용하여 570 nm의 파장에서 흡광도를 측정하였다. 이렇게 측정된 값을 이용하여 세포독성을 확인하였다. 각각의 추출물을 0.1, 0.5, 1, 2 mg/ml의 농도로 배지에 첨가한 후 세포 생존율을 MTT assay로 측정하였다.
Culturing the fibroblast cells of the CCRF mouse to stabilize after a frequency division number such as 8
상기 실험 결과, 경옥고 추출물의 경우 2 mg/ml의 농도에서도 86%의 세포 생존율을 나타내었으며, 1 mg/ml의 농도까지는 90%이상의 높은 세포 생존율을 나타내었다. 그러므로 경옥고 추출물은 세포생존력에 좋은 소재로서 확인 할 수 있었다. 산양삼추출물의 경우 2mg/ml의 농도에서 60%의 세포 생존율을 나타내었으며 경옥고 추출물에 비해 세포 생존율이 낮게 확인할 수 있었다. (도 1 및 도 2 참조)
As a result of the experiment, the jadeite extract showed 86% cell viability at a concentration of 2 mg / ml, and a high cell viability of 90% or more up to a concentration of 1 mg / ml. Therefore, jadeite extract could be identified as a good material for cell viability. Goat ginseng extract showed 60% cell viability at the concentration of 2mg / ml, and cell viability was lower than that of jadeite extract. (See Figures 1 and 2)
실험예 2. 경옥고 및 산양삼 추출물의 항산화 활성 검증Experimental Example 2. Antioxidant Activity of Gyogogo and Goat Ginseng Extracts
상기 실시예에서 얻은 시료의 항산화활성을 확인하기 위하여 문헌에 기재된 방법을 응용하여 하기와 같이 실험을 수행하였다 (Blois MS. 1958. Nature 181:1199-1203.)
In order to confirm the antioxidant activity of the sample obtained in the above example, the experiment was performed by applying the method described in the literature (Blois MS. 1958. Nature 181: 1199-1203.)
발포정 개발의 기능성을 가미하기 위하여 경옥고 추출물과 산양삼추출물을 첨가하여 제조하였다. 이러한 소재는 항산화활성이 뛰어난 것으로 알려진 소재이며 항산화에 관련된 기능성으로는 노화방지, 동맥경화, 염증억제, 바이러스억제, 감기억제, 생리적장해억제, 내병해성향상, 내스트레스성, 소화율향상, 장내미생물의 안정 등에 메카니즘을 가진 것으로 알려져 있어 항산화에 대한 효능을 확인하였다(Son SH et al., 1999. Biotechnol. Bioprocess Eng. 4: 119-123). 양성 대조군(Positive control)로는 지금까지 황산화 활성이 가장 뛰어난 것으로 알려진 BHA(Butylated hydroxyanisole)와 vitamin C를 대상으로 비교하였다.
To add the functionality of the effervescent tablet development was prepared by the addition of jadeite extract and goat ginseng extract. These materials are known to have excellent antioxidant activity. Antioxidant-related functions include anti-aging, arteriosclerosis, inflammation inhibition, virus inhibition, cold inhibition, physiological disorders, improvement of disease resistance, stress resistance, digestibility improvement, and intestinal microorganisms. It is known to have a mechanism such as stability and confirmed the efficacy on antioxidant (Son SH et al ., 1999. Biotechnol. Bioprocess Eng. 4: 119-123). As a positive control, BHA (Butylated hydroxyanisole) and vitamin C, which are known to have the highest sulfate activity, have been compared.
2.1. 전자공여(2.1. Electron donation DPPHDPPH ) 활성 측정) Active measurement
발포정에 항산화 효능을 가진 소제로서 경옥고 추출물과 산양삼 추출물을 이용하여 확인하기위하여 전자공여(DPPH) 활성을 실험하였다. 각 시료의 1,1-diphenyl-2-picryl hydrazyl(DPPH)에 대한 전자공여 효과로써 시료의 환원력을 측정 하였다. 즉 각추출물을 농도별로 제조한 시료 1 mL 에 0.4 mM DPPH 용액 0.5 mL 를 가하고, 10초간 vortex mixing 후 37 ℃에서 30분간 반응시킨 다음에 이 반응액을 분광광도계를 사용하여 517 nm에서 흡광도를 측정하였다.Electron-donating (DPPH) activity was tested to confirm the use of jadeite extract and goat ginseng extract as anti-oxidant agents in effervescent tablets. The reducing power of the sample was measured by the electron donating effect on 1,1-diphenyl-2-picryl hydrazyl (DPPH) of each sample. That is, 0.5 mL of 0.4 mM DPPH solution was added to 1 mL of each sample prepared for each concentration, and the reaction solution was reacted for 30 minutes at 37 ° C after vortex mixing for 10 seconds, and then the absorbance was measured at 517 nm using a spectrophotometer. It was.
본 실험 결과, 추출물을 0.1, 0.5, 1, 2 mg/ml 농도로 전자공여(DPPH) 활성억제력을 확인하여 본 결과 항산화 효능에 있어서 2 mg/ml 농도에서 경옥고추출물의 경우 80% 이상의 억제력을 확인하였으며 산양삼추출물의 경우 85%의 억제효능을 확인 할 수 있었다. 이러한 결과는 positive control로 이용된 단일물질인 BHA(Butylated hydroxyanisole)에 비해 추출물인 경옥고추출물과 산양삼추출물이 높게 나타났다. (도 3 참조)
As a result of the experiment, the extracts were confirmed to have an inhibitory effect on the electron donor (DPPH) activity at concentrations of 0.1, 0.5, 1, and 2 mg / ml. As a result, the antioxidant activity was found to be 80% or higher in the jadeite extract at the concentration of 2 mg / ml. In case of goat ginseng extract, the inhibitory effect of 85% was confirmed. These results showed that jadeite and goat ginseng extracts were higher than BHA (Butylated hydroxyanisole), which was used as a positive control. (See Fig. 3)
2.2. 2.2. SODSOD -- likelike 활성 측정 Active measurement
발포정 소재로 활용할 경옥고추출물과 산양삼추출물을 이용하여 항산화효과를 확인하기 위해 SOD-like activity를 실험하였다.SOD-like activity was tested to examine the antioxidant effects using jadeite extract and goat ginseng extract.
각 시료 0.2 mL 에 pH 8.5로 보정한 tris-HCl buffer (50 mM tris[hydroxymethyl] aminomethane + 10 mM EDTA) 3 mL 와 7.2mM pyrogallol 0.2 mL 를 가하고 25 ℃에서 10분간 방치 후 1 N HCl 1 mL로 반응을 정지 시킨 후 420 nm 에서 흡광도를 측정하여 나타내었다.3 mL of tris-HCl buffer (50 mM tris [hydroxymethyl] aminomethane + 10 mM EDTA) and 0.2 mL of 7.2 mM pyrogallol were added to 0.2 mL of each sample, and the mixture was left at 25 ° C for 10 minutes, followed by 1 mL of 1 N HCl. After stopping the reaction, the absorbance at 420 nm was measured.
본 실험 결과, 추출물을 0.1, 0.5, 1, 2 mg/ml 농도로 SOD-like activity를 확인하여 본 결과 2 mg/ml 농도에서 경옥고추출물의 경우 78% 의 억제력을 확인하였으며 산양삼추출물의 경우 88%의 억제효능을 확인할 수 있었다. 이러한 결과는 천연소재로서 항산화효은이 가장 높게 나타난 vitamin C를 positive control로 이용하여 비교하여 본 결과 단일물질인 vitamin C에 비해 추출물인 경옥고추출물은 활성이 낮았지만 산양삼 추출물의 경우에 높게 나타났다(도 4 참조).
As a result of this study, the SOD-like activity of the extracts at 0.1, 0.5, 1, and 2 mg / ml concentrations showed 78% inhibition of jadeite extract at 2 mg / ml concentration and 88% of goat ginseng extract. The inhibitory effect of was confirmed. These results were compared with vitamin C, which showed the highest antioxidant efficacy as a natural material, as a positive control. As a result, the jadeite extract, which is an extract, was lower in activity than the vitamin C, which is a single substance, but was higher in the case of goat ginseng extract (see FIG. 4). ).
2.3. 2.3. XanthineXanthine oxidaseoxidase 저해활성 측정 Measurement of inhibitory activity
발포정 소재로 활용할 경옥고추출물과 산양삼추출물을 이용하여 다른 실험방법에 의해 항산화효과를 확인하기 위해 Xanthine oxidase 저해활성을 실험하였다.Xanthine oxidase inhibitory activity was tested to examine the antioxidant effect by the different experimental methods using jadeite extract and goat ginseng extract.
시료용액 0.1 mL 와 pH 7.5의 0.1M potassium phosphate buffer 0.6 mL에 2 mM xanthine을 녹인 기질액 0.2 mL를 첨가하고 0.2 unit/mL xanthine oxidase 0.1 mL를 가하여 37 ℃에서 5분간 반응시킨 후 1N HCl 1mL를 가하여 반응을 종료시킨 다음, 반응액 중에 생성된 uric acid를 흡광도 292 nm 에서 측정하였다. Xanthin oxidase 저해 활성은 시료용액의 첨가군과 무첨가군의 흡광도 감소율로 나타내었다.
Add 0.1 mL of the sample solution and 0.2 mL of 2 mM xanthine substrate solution to 0.6 mL of 0.1 M potassium phosphate buffer at pH 7.5, add 0.1 mL of 0.2 unit / mL xanthine oxidase, and react for 5 minutes at 37 ° C. After completion of the reaction, uric acid generated in the reaction solution was measured at an absorbance of 292 nm. Xanthin oxidase inhibitory activity was shown by the absorbance decrease rate of the sample solution addition group and no addition group.
본 실험 결과, 추출물을 0.1, 0.5, 1, 2 mg/ml 농도로 Xanthine oxidase 저해활성을 확인하여 본 결과, 2 mg/ml 농도에서 경옥고 추출물의 경우에 77% 의 억제력을 확인하였으며 산양삼추출물의 경우 82%의 억제효능을 확인할 수 있었다. 이러한 결과는 양성 대조군으로 이용된 단일물질인 BHA의 84%에 비해 추출물인 경옥고추출물은 활성이 낮았지만 산양삼 추출물의 경우 비슷하게 나타났다(도 5 참조).
As a result, Xanthine oxidase inhibitory activity of the extract at 0.1, 0.5, 1, 2 mg / ml concentration was confirmed. As a result, the inhibitory activity of 77% was observed in the jadeite extract at 2 mg / ml concentration. An inhibitory effect of 82% was confirmed. These results showed that the jadeite extract, which had a lower activity than the 84% of BHA, a single substance used as a positive control, had a lower activity, but was similar for goat ginseng extract (see FIG. 5).
상기한 바와 같이, 경옥고 추출물과 산양삼 추출물을 이용하여 발포정기능성 소재로 개발하기 위해 확인한 결과, 경옥고 추출물에 비해 산양삼 추출물의 항산화 효능이 대체적으로 높게 나타났으며 항산화효능이 가장 높은 소재를 positive control로 비교하여도 활성이 떨어지지 않고 비슷하거나 높게 나타났다.As described above, as a result of confirming to develop effervescent functional material by using jadeite extract and goat ginseng extract, the antioxidant effect of goat extract was generally higher than that of jadeite extract, and the material with the highest antioxidant effect was positive control. In comparison, the activity did not drop and was similar or higher.
실험예Experimental Example
3. 한약재 추출물의 3. Herbal Medicine Extract
발포정Effervescent tablet
개발 효과 검증 Development effect verification
상기 실시예에서 얻은 시료의 발포효과를 확인하기 위하여 문헌에 기재된 방법을 응용하여 하기와 같이 실험을 수행하였다(Blois MS. 1958. Nature 181:1199-1203.).In order to confirm the foaming effect of the sample obtained in the above example, the experiment was performed by applying the method described in the literature (Blois MS. 1958. Nature 181: 1199-1203.).
하기 표 3과 같이 발포성분 및 그 함량에 따라 시료의 발포효과를 확인하는 실험을 수행하였다.Experiment to confirm the foaming effect of the sample according to the foaming component and its content as shown in Table 3.
(%)Mixing ratio
(%)
(mg)Unit weight
(mg)
셀룰로오스칼슘Carboxymethyl
Cellulose calcium
(우유/미국산),
덱스트린 5%Lactose 95%
(Milk / U.S.),
Dextrin 5%
본 실험 결과, 용해시간은 2분 내외이며, 부원료인 탄산수소나트륨함량 면에서, 10%, 25%인 경우는 탄산수소나트륨의 함량에 관계없이 거의 동일하게 용해되었으며, 추출분말이 15%인 경우(추출 분말로 작업)는 용해 속도가 상당히 느림을 확인하였고 경옥고를 첨가할 경우에는 액상형태로 첨가할 필요성을 확인하였으며, 또한 추출분말을 넣을 경우에는 용해속도는 느리나 발포 염류의 용량은 10~25% 이내에서 사용함이 바람직함을 확인하였다(도 6 참조).As a result of this experiment, the dissolution time was about 2 minutes, and in terms of the content of sodium hydrogen carbonate as an auxiliary material, 10% and 25% were dissolved almost the same regardless of the content of sodium hydrogen carbonate, and the extraction powder was 15%. (Working with extract powder) confirmed that the dissolution rate was considerably slow, and when jadeite was added, it was necessary to add it in liquid form.In addition, when the extract powder was added, the dissolution rate was slow but the volume of the foamed salt was 10 ~. It was confirmed that use within 25% is preferred (see Fig. 6).
Claims (20)
(1)비타민 2 내지 14 중량%, 한약재추출물 또는 경옥고 1 내지 18중량%, 유기산 1 내지 14 중량%, 당알콜 1 내지 12중량%을 혼합하여 제 1혼합물을 얻고, 상기 제 1혼합물에 아미노산 0.5 내지 2중량%, 향료 6 내지 10중량%, 식염 0.2 내지 0.6중량%, 식품첨가물 1 내지 2중량%, 및 감미제 1 내지 2중량%를 혼합하여 제 2혼합물을 얻는 제 1 단계; (2)상기 제 1혼합물 및 제 2 혼합물을 혼합한 다음에 상기 혼합물에 안정제 1 내지 12중량%을 첨가하여 혼합하는 제 2단계; (3)상기 (2)단계의 안정제가 첨가된 혼합물에 결합제 20 내지 40중량% 및 발포제를 4 내지 56 중량%를 첨가하고 혼합하는 제 3 단계; (4) 상기 (3)단계의 혼합물에 활택제 1 내지 12중량%의 양; 및 붕해제, 착색제 및 보존제를 합쳐 약 30 내지 90 중량%를 첨가하고 혼합하는 제 4 단계; 상기 제 4단계의 혼합물을 타정하는 제 5단계 공정을 포함하는 경옥고 또는 산양삼 추출물을 함유한 발포정의 제조방법.The method of claim 1,
(1) 2 to 14% by weight of vitamins, 1 to 18% by weight of herbal extract or jadeite, 1 to 14% by weight of organic acid, and 1 to 12% by weight of sugar alcohol to obtain a first mixture, and 0.5 to amino acids of the first mixture. A first step of mixing a 2 wt%, 6-10 wt% fragrance, 0.2-0.6 wt% salt, 1-2 wt% food additive, and 1-2 wt% sweetener to obtain a second mixture; (2) a second step of mixing the first mixture and the second mixture followed by adding 1 to 12% by weight of a stabilizer to the mixture; (3) a third step of adding and mixing 20 to 40% by weight of the binder and 4 to 56% by weight of the blowing agent to the mixture to which the stabilizer of step (2) is added; (4) the amount of the lubricant 1 to 12% by weight in the mixture of step (3); And a fourth step of adding and mixing about 30 to 90% by weight of the disintegrant, the colorant, and the preservative together; Method for producing effervescent tablet containing jadeite or goat ginseng extract comprising the fifth step of the step of tableting the mixture of the fourth step.
상기 제조방법의 제 1 단계에서 상기 비타민은 비타민 C, 또는 비타민 B1, 비타민 B2, 비타민 B6, 비타민 B12, 니코틴산아미드, 판토텐산, 비오틴, 엽산 중에서 선택된 어느 하나 이상의 비타민임을 특징으로 하는 제조방법.The method of claim 1,
In the first step of the manufacturing method, the vitamin is vitamin C, or any one or more vitamins selected from vitamin B1, vitamin B2, vitamin B6, vitamin B12, nicotinic acid amide, pantothenic acid, biotin, folic acid.
상기 제조방법의 제 1 단계에서 상기 유기산은 구연산(citric acid), 사과산(maleic acid), 젖산(lactic acid), 주석산(tartaric acid), 호박산(succinic acid), 또는 푸마릭산(fumaric acid) 중에서 선택된 어느 하나 이상임을 특징으로 하는 제조방법.The method of claim 1,
In the first step of the manufacturing method, the organic acid is selected from citric acid, maleic acid, lactic acid, lactic acid, tartaric acid, succinic acid, or fumaric acid. Method for producing any one or more.
상기 제조방법의 제 1 단계에서 상기 한약재는 산양삼, 홍삼, 오가피, 오미자, 당귀, 구기자, 사상자, 복분자, 토사자, 천궁, 천마, 건강, 또는 대추임을 특징으로 하는 제조방법.The method of claim 1,
In the first step of the manufacturing method, the herbal medicine is goat ginseng, red ginseng, ogapi, Schisandra chinensis, Angelica, Gugija, casualty, Bokbunja, Tosa, Cheongung, Cheonma, Health, or jujube.
상기 제조방법의 제 1 단계에서 상기 경옥고는 인삼 1 내지 6 중량%, 하수오 3 내지 15 중량%, 생지황 20 내지 40 중량%, 복령 2 내지 10 중량%, 지구목 10 내지 20 중량%, 맥문동 1 내지 6 중량%, 갈 근 1 내지 10 중량% 및 꿀 10 내지 30 중량%의 조성으로 구성됨을 특징으로 하는 제조방법.The method of claim 1,
In the first step of the production method, the jadeite is 1 to 6% by weight of ginseng, 3 to 15% by weight of sewage, 20 to 40% by weight of raw sulfur, 2 to 10% by weight of Fuling, 10 to 20% by weight of earthworm, 1 to 1 6 wt%, brown root 1-10 wt% and honey 10-30 wt%.
상기 제조방법의 제 1 단계에서 상기 제 1혼합물로서, 상기 당알콜은 만니톨 (mannitol), 솔비톨(sorbitol), 말티톨(maltito) 자일리톨(xylitol), 에리스리톨(Erythritol), 락티톨(lactitol), 글리시톨(glicitol), 리비톨(Ribitol), 갈락티톨(galactitol) 중에서 선택된 어느 하나 이상의 당알콜임을 특징으로 하는 제조방법.The method of claim 1,
As the first mixture in the first step of the manufacturing method, the sugar alcohol is mannitol, sorbitol, maltito xylitol, erythritol, lactitol, glycitol (Glicitol), ribitol (Ribitol), galactitol (galactitol) is any one or more of the production method characterized in that the sugar alcohol.
상기 제조방법의 제 1 단계에서 제 2혼합물로서 상기 아미노산은 타우린(Taurine), 아스파틱산(Aspartic acid), 쓰레오닌(Threonine), 세린(Serine), 글루타믹산(Glutamic acid), 프롤린(Proline), 글리신(Glycine), 알라닌(Alanine), 시스테인(Cysteine), 발린(Valine), 메티오닌(Methionine), 이소류신(Isoleucine), 티로신(Tyrosine), 페닐알라닌(Phenylalanine), 트립토판(Tryptophane), 리신(Lysine), 히스티딘(Histidine), 아르기닌(Arginine) 중에서 선택된 어느 하나 이상임을 특징으로 하는 제조방법.The method of claim 1,
As a second mixture in the first step of the preparation method, the amino acid is taurine, aspartic acid, threonine, serine, glutamic acid, proline, or proline. ), Glycine, Alanine, Cysteine, Valine, Methionine, Isoleucine, Tyrosine, Phenylalanine, Tryptophane, Lysine (Lysine) ), Histidine (Histidine), arginine (Arginine) any one or more selected from the manufacturing method.
상기 제조방법의 제 1 단계에서 제 2혼합물로서 상기 향료는 파인애플향, 사과향, 오렌지향, 레몬향, 포도향, 체리향, 복숭아향, 살구향, 딸기향, 망고향, 라임향, 메론향, 매실향, 오디향, 복분자향, 인삼향, 홍삼향, 대추향, 생강향, 유자향 중에서 선택된 어느 하나 이상임을 특징으로 하는 제조방법.The method of claim 1,
As a second mixture in the first step of the manufacturing method, the flavor is pineapple flavor, apple flavor, orange flavor, lemon flavor, grape flavor, cherry flavor, peach flavor, apricot flavor, strawberry flavor, mango flavor, lime flavor, melon flavor, Method of producing at least one selected from plum flavor, mulberry flavor, bokbunja flavor, ginseng flavor, red ginseng flavor, jujube flavor, ginger flavor, citron flavor.
상기 제조방법의 제 1 단계에서 제 2혼합물로서 상기 식염은 염화칼륨(Potassium Chloride, KCl), 염화나트륨(NaCl) 중에서 선택된 어느 하나 이상임을 특징으로 하는 제조방법.The method of claim 1,
In the first step of the preparation method, the salt is the second mixture, wherein the salt is any one or more selected from potassium chloride (Potassium Chloride, KCl) and sodium chloride (NaCl).
상기 제조방법의 제 1 단계에서 제 2혼합물로서 상기 식품첨가물은 글루콘산 나트륨(Sodium Gluconate, C 6 H 11O 7 Na)임을 특징으로 하는 제조방법.The method of claim 1,
The food additive as a second mixture in the first step of the manufacturing method is sodium gluconate (Sodium Gluconate, C 6 H 11 O 7 Na) characterized in that the manufacturing method.
상기 제조방법의 제 1 단계에서 제 2혼합물로서 상기 감미제는 아스파탐, 설탕, 사카린, 아세설팜칼륨, 스테비오사이드, 포도당, 과당, 설탕 중에서 선택된 어느 하나 이상임을 특징으로 하는 제조방법.The method of claim 1,
The sweetener as a second mixture in the first step of the production method is any one or more selected from aspartame, sugar, saccharin, acesulfame potassium, stevioside, glucose, fructose, sugar.
상기 제조방법의 제 2 단계에서 상기 안정제는 제삼인산칼슘, 제일인산칼슘, 주석산나트륨(Sodium Tartrate), 푸마르산나트륨(Mono Sodium Fumarate), D-L 말산 중에서 선택된 어느 하나 이상임을 특징으로 하는 제조방법.The method of claim 1,
In the second step of the preparation method, the stabilizer is any one or more selected from calcium triphosphate, calcium phosphate monobasic, sodium tartrate (Sodium Tartrate), sodium fumarate (Mono Sodium Fumarate), DL malic acid.
상기 제조방법의 제 3 단계에서 상기 결합제는 유당, CMC-Ca, 물, 유기용매, 폴리비닐피롤리돈, 히드록시프로필셀룰로오스, 미결정셀룰로오스, 히드록시프로필메틸셀룰로오스, 덱스트린, 젤라틴, 메틸셀룰로오스, 히드록시셀룰로오스,히드록시메틸셀룰로오스, 폴리비닐알콜, 예비-젤라틴화된 전분(Pregelatinized Starch) 또는 아라비아 검으로부터 선택되는 1종 이상임을 특징으로 하는 제조방법.The method of claim 1,
In the third step of the preparation method, the binder is lactose, CMC-Ca, water, an organic solvent, polyvinylpyrrolidone, hydroxypropyl cellulose, microcrystalline cellulose, hydroxypropylmethyl cellulose, dextrin, gelatin, methyl cellulose, and hydride. At least one selected from hydroxycellulose, hydroxymethyl cellulose, polyvinyl alcohol, pre-gelatinized starch, or gum arabic.
상기 제조방법의 제 3 단계에서 상기 발포제를 탄산수소나트륨, 중탄산나트륨(Sodium Bicarbonate, NaHCO3)으로부터 선택되는 1종 이상임을 특징으로 하는 제조방법.The method of claim 1,
In the third step of the production method, the blowing agent is characterized in that at least one selected from sodium bicarbonate, sodium bicarbonate (Sodium Bicarbonate, NaHCO 3 ).
상기 제조방법의 제 4 단계에서 상기 활택제는 스테아린산 마그네슘(Mg Stearate), 탈크, 스테아린산 또는 무수경질규산(SiO2)으로 이루어진 1종 이상의 혼합물임을 특징으로 하는 제조방법.The method of claim 1,
In the fourth step of the production method, the glidant is characterized in that at least one mixture consisting of magnesium stearate (Mg Stearate), talc, stearic acid or light silicic anhydride (SiO 2 ).
상기 제조방법의 제 4 단계에서 상기 붕해제는 전분글리콜레이트나트륨, 크로스포비돈(Crospovidone), 크로스-링크드 카르복시메틸셀룰로오스소듐염(Cross-linked sodium carboxymethyl cellulose), 저치환 히드록시프로필셀룰로오스(Low Substituted Hydroxypropylcellulose), 히드록시프로필메틸셀룰로오스, 폴리비닐피롤리돈, 전분, 카복시메틸셀룰로오스칼슘 및 이들의 조합으로 이루어진 1종 이상임을 특징으로 하는 제조방법.The method of claim 1,
In the fourth step of the preparation method, the disintegrant is starch glycolate sodium, crospovidone, cross-linked sodium carboxymethyl cellulose, low-substituted hydroxypropylcellulose. ), Hydroxypropyl methyl cellulose, polyvinylpyrrolidone, starch, carboxymethyl cellulose calcium, and a combination thereof.
상기 제조방법의 제 4 단계에서 상기 착색제를 이산화티탄, 산화철, 탄산마그네슘, 황산칼슘, 산화마그네슘, 수산화마그네슘 또는 알루미늄레이크 (aluminium lake)등에서 선택된 1종 이상임을 특징으로 하는 제조방법.The method of claim 1,
In the fourth step of the manufacturing method, the coloring agent is at least one selected from titanium dioxide, iron oxide, magnesium carbonate, calcium sulfate, magnesium oxide, magnesium hydroxide or aluminum lake (aluminium lake).
상기 제조방법의 제 4 단계에서 상기 보존제는 벤조인산, 메틸파라벤, 에틸파라벤 또는 프로필 파라벤으로부터 선택된 1종 이상임을 특징으로 하는 제조방법.The method of claim 1,
In the fourth step of the production method, the preservative is characterized in that at least one selected from benzoic acid, methyl paraben, ethyl paraben or propyl paraben.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120054704A KR20130130995A (en) | 2012-05-23 | 2012-05-23 | A preparation method of an effervescent tablet comprising an extract of kyungokgo or crude drug |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120054704A KR20130130995A (en) | 2012-05-23 | 2012-05-23 | A preparation method of an effervescent tablet comprising an extract of kyungokgo or crude drug |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20130130995A true KR20130130995A (en) | 2013-12-03 |
Family
ID=49980375
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120054704A KR20130130995A (en) | 2012-05-23 | 2012-05-23 | A preparation method of an effervescent tablet comprising an extract of kyungokgo or crude drug |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20130130995A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160066767A (en) * | 2014-12-03 | 2016-06-13 | 라원택 | A method for preparing the powder preparation of Kyung-ok-go containing abundant active-ingredient |
WO2020209427A1 (en) * | 2019-04-12 | 2020-10-15 | 주식회사 비엔지삶 | Food composition comprising palmyra palm, ginseng, and artichoke as active ingredient, foaming agent using same, and preparation method therefor |
KR20210048138A (en) * | 2019-10-23 | 2021-05-03 | 주식회사 한국인삼공사 | Method for Preparing Pills Comprising Ginseng |
KR20210086038A (en) * | 2019-12-31 | 2021-07-08 | 진안당 영농조합법인 | Method for producing red ginseng foaming tablet and red ginseng foaming tablet produced by the same method |
KR20220108437A (en) * | 2021-01-27 | 2022-08-03 | 충청대학교 산학협력단 | Method for manufacturing effervescent vitamin preparation |
KR102461437B1 (en) * | 2022-05-02 | 2022-11-02 | 최진원 | Pharmaceutical composition for preventing or treating obesity having garcinia cambogia extract and health functional food having the same |
-
2012
- 2012-05-23 KR KR1020120054704A patent/KR20130130995A/en not_active Application Discontinuation
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160066767A (en) * | 2014-12-03 | 2016-06-13 | 라원택 | A method for preparing the powder preparation of Kyung-ok-go containing abundant active-ingredient |
WO2020209427A1 (en) * | 2019-04-12 | 2020-10-15 | 주식회사 비엔지삶 | Food composition comprising palmyra palm, ginseng, and artichoke as active ingredient, foaming agent using same, and preparation method therefor |
KR20210048138A (en) * | 2019-10-23 | 2021-05-03 | 주식회사 한국인삼공사 | Method for Preparing Pills Comprising Ginseng |
KR20210086038A (en) * | 2019-12-31 | 2021-07-08 | 진안당 영농조합법인 | Method for producing red ginseng foaming tablet and red ginseng foaming tablet produced by the same method |
KR20220108437A (en) * | 2021-01-27 | 2022-08-03 | 충청대학교 산학협력단 | Method for manufacturing effervescent vitamin preparation |
KR102461437B1 (en) * | 2022-05-02 | 2022-11-02 | 최진원 | Pharmaceutical composition for preventing or treating obesity having garcinia cambogia extract and health functional food having the same |
WO2023214716A1 (en) * | 2022-05-02 | 2023-11-09 | (주)초이스메디케어 | Pharmaceutical composition and health functional food for preventing or obesity comprising garcinia cambogia extract |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101382400B1 (en) | Composition comprising Protaetia brevitarsis for preventing and treating Inflammatory Disorder | |
KR20130130995A (en) | A preparation method of an effervescent tablet comprising an extract of kyungokgo or crude drug | |
KR20130036800A (en) | A composition for stimulating immune response comprising an extract of angelicae gigantis radix and astragali radix | |
US20230082624A1 (en) | Composition, containing quisqualis indica extract, for preventing or treating prostatic hyperplasia | |
KR101045031B1 (en) | A composition comprising fruits of Cudrania tricuspidata for immunopotentiating | |
KR102366919B1 (en) | Functional health food composition for inhibiting muscle reduction comprising a mixed extract of mulberry twig, Eucommia bark, Acanthopanax, and black bean | |
US20170106040A1 (en) | Composition for preventing and treating male infertility, containing mixed herbal extract as active ingredient and use thereof | |
KR100824970B1 (en) | Polygoni cuspidati radix extract for allergic disease and process for preparation thereof | |
KR101731152B1 (en) | Anti-diabetic composition containing the extract of actinidia arguta leaves or fractions thereof | |
KR101151567B1 (en) | Composition comprising the extract of mixed crude drug showing anti-allergic Effect | |
KR20150031373A (en) | Phamaceutical and food composition for preventing or treating obesity comprising extract of leaf from Hoppophea rhamnoids as effective component | |
KR101344189B1 (en) | A Composition comprising an extract of fermented or non-fermented Lonicerae Flos and Citri Reticulatae Pericarpium for treating or preventing obesity | |
KR101503792B1 (en) | Neuroprotective composition comprising extract or fractions of Vaccinium uliginosum as an active ingredient | |
KR20210140933A (en) | Composition for preventing or treating sarcopenia comprising blueberry extract | |
KR20210147247A (en) | A composition for immune enhancement comprising narrow-leaf erecta fig extract mixture | |
KR20110030875A (en) | A composition for preventing and treating bone diseases comprising the extract of herbal medicine | |
KR100750879B1 (en) | A pharmaceutical composition comprising the extract of Meliae Cortex for treating or preventing allergic disease | |
KR101803046B1 (en) | Anti-cancer composition comprising alcohol extracts of Selaginella tamariscina as an active ingredient for combinational administration with chemotherapeutics | |
KR101454336B1 (en) | Compositions for preventing and treating arthritis | |
KR20180136592A (en) | Composition for anticancer containing extract of Jeju camellia mistletoe | |
KR20130032720A (en) | A composition comprising the extract of melia azedarach showing anti-cancer activity against stomach tumor | |
KR20120073797A (en) | Pharmaceutical composition comprising for preventing and treating an articular rheumatism, extract from the mixture of ponciri fructus, lonicerae flos and angelicae dahuricae radix | |
KR20130065117A (en) | Composition comprising water extracts from tremella foliacea fr. for treating or preventing obesity | |
WO2013133677A1 (en) | Composition containing reaction mixture of red-ginseng extract and persimmon vinegar for preventing or treating vascular diseases | |
KR20090074337A (en) | Composition for treating and preventing hypertension comprising the extract of taraxacum mongolicum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E90F | Notification of reason for final refusal | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |